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NATURAL AND EXOGENOUS GENOME EDITING IN WISKOTT-ALDRICH
SYNDROME PATIENT CELLS

Tamara Jatoba Laskowski, B.S.
Advisory Professor: Brian R. Davis, Ph.D.
Wiskott-Aldrich syndrome (WAS) is an X-linked primary immunodeficiency
disease characterized by thrombocytopenia, recurrent infections and increased
autoimmunity. This disease is caused by mutations in the WAS gene (WAS) which
encodes for the WAS protein (WASp), exclusively expressed in hematopoietic cells
and required for proper platelet production and lymphoid cell function.
Approximately 11% of patients with WAS exhibit a phenomenon called Somatic
Revertant Mosaicism which is characterized by the presence of lymphocytes which
naturally revert back to normal phenotype by restoring WASp expression. To date,
the mechanisms of this naturally-occurring gene therapy remains poorly
understood, and the full extent of the repertoire of revertant genotypes has not yet
been elucidated. The remaining 89% of WAS patients require treatment early in life,
or the disease leads to premature death. At present, cure for WAS can only be
attained through allogeneic stem cell transplantation or lentiviral hematopoietic stem
cell gene therapy.
In this work, we focused on both groups of WAS patients. In order to gain
insight into the extent of the revertant repertoire in WAS revertant patients, we used
next generation sequencing technology to analyze DNA from WASp+ T-cells
isolated from two revertant patients carrying the same germline mutation. We
viii

identified over a hundred different revertant genotypes. In this report we describe
those which directly reverted the original germline mutation, as well as those which
are believed to provide a compensatory effect by inducing alternative splicing. Our
findings represent, to our knowledge, the first report of ultra-deep analysis of
somatic reversions in WAS patients.
In our study of non-revertant WAS patients, we investigated restoration of Tand NK-cell functionality following an in vitro virus-free zinc-finger nuclease (ZFN)mediated genome editing strategy for correction of WAS mutations. We generated
induced pluripotent stem cells (iPSC) from skin fibroblasts of a WAS patient carrying
an insertional frame-shift mutation. Subsequently, a WAS-2A-eGFP transgene was
targeted at the endogenous chromosomal location by homology-directed repair
using ZFN, thereby correcting the gene defect and creating a GFP reporter for
WASp expression. Hematopoietic progenitor cells were generated from WAS iPSC
and gene-corrected iPSC (cWAS) in vitro via spin embryoid bodies. Human
embryonic stem cell lines WA01 and WA09 were used as control. GFP expression
was pronounced in all CD43+ hematopoietic lineages including myeloid, monocytic,
lymphoid, erythroid and megakaryocytic lineages. Hematopoietic precursors were
further cultured on OP9-DL1 to generate NK cells. NK cells were readily obtained
from cWAS and WA01/WA09 progenitors, but to a far more limited extent from WAS
progenitors. WAS-derived NK cells were unable to generate interferon-γ or tumor
necrosis factor-α upon stimulation with K562. Cytokine production was restored in
cWAS-derived NK cells.
Taken together these results indicate that targeted endogenous integration of
ix

the WAS gene in WAS-iPSC results in restoration of the lymphoid defect observed
in WAS-iPSC. Transplantation of gene-corrected iPSC-derived hematopoietic
precursors may offer an alternative to lentiviral gene therapy which carries an
inherent risk for insertional oncogenesis.
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CHAPTER 1: BACKGROUND AND INTRODUCTION

1.1 Wiskott-Aldrich Syndrome (WAS)
Wiskott-Aldrich

Syndrome

(WAS)

is

a

monogenic

X-linked

primary

immunodeficiency (PID) disorder characterized by microthrombocytopenia, severe
eczma, recurrent infections, autoimmunity, and malignancies [1]. WAS was first
described in 1937 by Alfred Wiskott though his evaluation of three brothers who
presented with bloody diarrhea, eczema, microthrombocytopenia, episodes of fever,
and recurrent ear infections. Because their sisters were not affected, Dr. Wiskott
proposed the boys were afflicted with a novel hereditary thrombocytopenia [2]. In
1954, Robert Aldrich reported similar clinical findings in sixteen out of forty males,
but not in any females, from a single family he studied over six generations.
Through this study, he demonstrated the X-linked mode of inheritance of this
disease [2, 3]. The disease was then named Wiskott-Aldrich Syndrome (WAS), after
the two physicians who first described it.
The gene implicated in Wiskott-Aldrich Syndrome was identified much later, in
1994, through the work of Jonathan Derry, Hans Ochs, and Uta Francke [4].
Linkage analysis studies led to localization of the WAS gene at a region in Xp11.22p11.23. Through the use of positional cloning strategies followed by evaluation of
potential cDNA candidates, they were able to identify a sequence whose expression
was detected only in cells of lymphocytic and megakaryocytic lineages, and was
affected in patients diagnosed with WAS.
1

Led by the identification of DNA

mutations in this sequence in four patients with classical WAS they postulated this
newly-identified gene sequence was indeed the WAS gene [4].
The WAS gene is comprised 12 exons, which encode a 502-amino acid-long
intracellular protein, expressed exclusively in cells of the hematopoietic system [46]. The WAS protein (WASp) has an intricate domain architecture comprised of
WAS homology domain 1 (WH1), Cdc42/Rac GTPase binding domain (GBD),
proline-rich domain, G-actin binding verprolin homology domain (V), cofilin
homology domain (C), and a C-terminal acidic segment (A) [7]. The function of the
WASp is not yet completely understood, however studies have reported it is
associated with signal transduction pathways involved in actin polymerization and
cytoskeletal reorganization [8-10] The VCA domains of WASp are described as the
catalytic domains of the protein and interact with the Arp2/3 complex to activate
actin nucleation (Figure 1),

a process required for rearrangement of actin

cytoskeleton, which is necessary to support various cellular functions, such as
migration, vesicle trafficking, adhesion, and cell shape changes [10,11]. These
cytoskeleton remodeling processes are essential for normal function of immune
cells, including immunological synapse formation and activation of lymphocytes [7].

2

3

Figure 1: WASp plays a crucial role in activating the Arp2/3 complex and
mediating the synthesis of actin filaments. A. Organization of WASp domains
and the exons associated with protein domains; B. Representation of WASp
function in hematopoietic cell, interacting with Arp2/3 complex to mediate
polymerization of actin filaments.
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The absence of detectable WAS protein expression in hematopoietic cells is
what confers the classical Wiskott-Aldrich Syndrome phenotype previously
described. WASp deficiency can be caused by various possible mutations that may
occur along the 12 exons of the gene. Hundreds of mutations have been mapped to
the WAS gene [5, 12], and though classical WAS results in a severe clinical
phenotype, there is a range of clinical severity, with some mutations causing
decreased WASp expression, resulting in milder variants of WAS, typically referred
to as X-linked thrombocytopenia (XLT) [12]. For both classical WAS and XLT, the
mutations lead respectively to complete or partial loss of function of the gene.
However, more recently, studies have shown that certain mutations which cause
constitutive activation of WASp lead to X-linked Neutropenia (XLN) [13]. This
disease appears to occur more rarely, with only 4 mutations reported to date:
Leu270Pro, Ser270Pro, Ile276Ser, and Ile294Thr [12, 13].
The complications that result from the absence of WASp expression (giving rise
to classical WAS phenotype) affect nearly all cells of hematopoietic lineage, and
cause prominent immunologic impairments in both T-cell and B-cell function [14]. It
has been shown that WASp-deficient T-cells are unable to reach optimal levels of
activation through the T-cell receptor (TCR), and do not respond well to IL-2
stimulation [7,14-16]. Such impairments in T-cell function greatly contribute to the
immunodeficiency seen in WAS patients.

WAS-deficient B-cells have impaired

ability to home to secondary lymphoid organs, therefore compromising the patient’s
humoral response [14]. In addition to defects in T- and B-cells, Orange and
colleagues showed that in Natural-Killer (NK) cells harvested from WAS patients,
5

the absence of WASp expression correlated with significantly reduced cytolytic
function in chromium-release killing assays [17] Furthermore, WASp deficiency has
also been shown to affect the function of hematopoietic stem cells (HSCs). Lacout
et.al.(2003) [18] reported data from competitive transplantation studies in mice
suggesting that WASp plays a role in migration of HSCs, as well as engraftment of
these cells in the bone marrow.
Cure for WAS can only be achieved by an allogeneic hematopoietic stem cell
transplant (HSCT) from a genotypically-matched donor or by gene therapy. Though
transplants are often the recommended treatment, challenges in finding suitable
donors leave many patients with only the option to receive HSCT from mismatched
related donors, thereby decreasing the efficacy of transplant, and increasing the risk
of rejection [19].

1.2 Revertant Somatic Mosaicism in Wiskott-Aldrich Syndrome
Approximately 11% of WAS patients have been identified as having, in addition
to immune cells which carry the inherited germ line mutation, cells which have
undergone spontaneous genetic changes that resulted in reversion to normal
phenotype. The presence of both phenotypically normal and abnormal cells in vivo
is referred to as Revertant Somatic Mosaicism, and has been described in various
disorders affecting the hematopoietic system, the liver, and the skin [20-23].

6

Revertant patients often present milder clinical symptomatology and may not
require the more aggressive treatments that are commonly prescribed to nonrevertant patients. A significant factor likely contributing to the observation of
reversions in patients is the selective advantage in vivo for growth and proliferation
of cells which carry the wild-type gene product. The fact that Revertant Somatic
Mosaicism is reported in diseases affecting highly regenerative tissues capable of
rapid and robust cell division may suggest that significant cell proliferation is also an
important factor in supporting the origination of revertant cells [20,24].
The precise mechanisms whereby revertant cells emerge in WAS patients are
not yet known.

It is accepted that at least two events must occur: first, the

emergence of molecular reversions in the WAS gene, and subsequently the in vivo
selective expansion of these revertant cells [20]. Cells undergo random genetic
changes throughout their lives, and it is possible that one of these changes may
lead to partial or full restoration of expression of a gene product. These cells which
have restored their phenotype have a better chance for growth and proliferation,
thus accumulating in the patient over time [24]. Some studies of WAS have shown
that second-site compensatory mutations, or point mutations directly affecting the
mutant codon occurring during cell division may explain the origination of reversion
in the patient [25, 26]. In WAS revertants, the predominance of WASp-expressing
cells in some cell populations, such as T- and B-lympocytes confirms the selective
advantage conferred to cells which carry reversions that partially or fully restore
normal phenotype [27]. Furthermore, group demonstrated through clonal assay
analysis of WAS-patient-derived T-cells in vitro, a selective proliferative advantage
7

in cells which revealed, by sequence analysis, base-pair changes in the WAS gene,
which directly affected the mutated codon, or bypassed the mutation by inducing
alternative splicing [23].
The collective data reported in these various studies led to our interest in
establishing a methodology that allows for an in-depth investigation into the diversity
of the revertant repertoire in WAS revertant patients’cells. We analyzed cells from a
group of five WAS-revertant patients among whom there were three different germ
line mutations. Our findings reported herein result from a comprehensive
assessment of the various genotypic changes detected in the WASp-expressing
(WASp+) cells of these patients.

1.3 Gene Therapy for Wiskott-Aldrich Syndrome (WAS)
The vast majority of patients diagnosed with WAS present with the severe
clinical symptomatology that is the hallmark of this disease. For these patients, the
cure can only be achieved by an allogeneic hematopoietic stem cell transplant or
gene therapy. Transplant from an HLA-matched donor has a very high success
rate of conferring therapeutic benefit to the patient [28]. However, only one third of
patients receive a matched transplant [28]. For patients without matched donors,
gene therapy offers an alternative that can bring restoration of normal function in
hematopoietic cells.

8

Autologous transplantation of ex vivo genetically corrected hematopoietic
stem/progenitor cells (HSPCs) is a promising and attractive proposal for treatment
of inherited primary immunodeficiencies such as WAS. This approach can confer
upon the patient the clinical benefits of a transplant without the rejection risks
associated with it. Virus-mediated approaches have been investigated as a feasible
method to correct genetic mutations and rescue phenotype for several decades,
and started with the use of retroviral vectors [29]. In the mid 1980s, Williams’ and
Dick’s laboratories [30, 31] reported successful use of retrovirus for gene transfer
into bone marrow-derived murine HSC. In light of these promising preliminary
results, scientists became interested in applying this technology to treatment of
inherited diseases [15, 16, 28,29]. The first gene therapy clinical trial, conducted at
the National Institutes of Health (NIH), targeted T-lymphocytes of patients with
Adenosine Deaminase-Deficient SCID [32]. One renowned gene therapy trial was
conducted in Paris, France, and sought to treat patients with X-linked Severe
Combined Immunodeficiency (X-linked SCID).

In this trial, the patient’s derived

bone marrow HSCs were cultured ex-vivo and transduced by gammaretroviruses
before autologous transplantation [23]. The results of this trial were astonishingly
successful. Nine out of the ten patients treated showed rapid and vigorous Tlymphocyte production; however, four out of the nine patients developed T-cell
leukemia 31-68 months after treatment ended [33,34]. Further investigations into
the molecular mechanism responsible for this undesired effect revealed a vectormediated integration adjacent to a known proto-oncogene (LMO2), which trans-
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activated the expression of this gene and led to the aberrant T-lymphocyte
proliferation [34].
The SCID trial exposed one of the most significant concerns with gene
therapies for treatment of human diseases: the potential oncogenic effects induced
by transgene integration. Other, more recent trials for PID have reported aberrant
clonal proliferation due to undesired integrations [35]. Because integration in the
genome of the treated cells is a random process, there is an increased probability of
genotoxic effects due to deregulation of gene expression, which may occur as a
consequence of interactions between viruses and the human genome

[36-38].

These concerns led to advances in the development of safer gene delivery vectors.
New retroviral vectors were designed, now self-inactivating vectors (SIN-vectors),
capable of safer and more efficient performance [39-42]. Their self-inactivating longterminal repeats which reduce the potential for insertional activation of neighboring
alleles, minimizing the potential for undesired effects. [43].
Further, lentiviral vectors were found to successfully transduce hematopoietic
stem and progenitor cells (HSPCs), and in less time than gammaretroviruses [29
42, 44-45]. SIN versions of lentiviruses have also been designed and bring new
hope for safer and more efficient gene therapy protocols [42]. Recently, Aiuti et.al.
reported successful ex vivo correction of WAS defect in three WAS patients using
SIN lentivirus-mediated gene transfer into HSPCs. This treatment conferred
significant clinical improvement and restoration of immune function to patients, with
no evidence of adverse effects, as reported in a 30-month follow-up [46]. Though
results appear promising, integration site (IS) profiling analysis revealed an
10

estimated average vector copy number (VCN) of 2.3 in bulk-cultured CD34+ , and
2.6 VCN observed in T-cells. Integrations favored transcription unit sites and
clustered in gene-rich regions, with a total of approximately 10,000 to 25,000 unique
integrations per patient [46]. These data show that, even with the current state-ofthe art approaches for viral-mediated gene therapy, there remains a risk of adverse
side effects due to random transgene integration.

1.4 Site-specific genome editing
The extensive work accomplished in virus-mediated gene therapy studies
contributed significantly to a greater understanding of the underlying biological
events that cause potentially deleterious side effects in patients. Consequently, it
motivated the field to develop new technologies and safer approaches. One such
example is the emergence of site-specific genome editing strategies that utilize
engineered nucleases to target a specific locus on the genome for correction, thus
minimizing the risk of insertional mutagenesis. These nucleases are capable of
mediating genomic changes by inducing a sequence-specific double-strand break
(DSB), and thus stimulating the rapid non-homologous end-joining (NHEJ) repair
mechanism, or by facilitating homology-directed repair when co-delivered with a
custom homologous DNA template [47-50]. Currently there are three major custom
nuclease systems available: Zinc-Finger nucleases (ZFNs), transcription activatorlike effector nucleases (TALENs), and clustered regulatory interspaced short
palindromic repeat (CRISPR)-Caspase system. [51,52]. All three systems have their
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advantages and limitations. The major differences between them are related to
specificity, efficiency, and design flexibility [50]. ZFN and TALENs are engineered
endonucleases that contain sequence-specific DNA binding domains that are
derived from zinc- finger and transcription activator-like effector (TALE) proteins.
The versatility and programmability of DNA binding domains give ZFN and TALENs
a level of flexibility that permits targeting of virtually any site in the genome [52].
TALE proteins originate from the plant pathogenic bacteria of the genus
Xanthomonas, and their DNA recognition domains contain a series of 33-35-aminoacid repeat domains, each capable of recognizing a single base pair. Two
hypervariable amino acids, known as the repeat-variable di-residues, determine the
specificity of the TALE protein [52]. Multiple TALE repeats can be linked together to
provide recognition to desired DNA sequences.
The CRISPR/Cas system has recently emerged as an alternative for use in
genome editing strategies. This system offers a potentially simple and inexpensive
option for inducing site-specific genetic modifications. CRISPRs are components of
an adaptive immune system that exists in bacteria and archea and relies on small
RNAs for sequence-specific detection and cleavage of invading foreign DNA [52,
53]. In the CRISPR/Cas system, short sequences from the invading DNA are
integrated into the CRISPR genomic loci and subsequently transcribed and
processed to generate crRNA. These, in turn, bind to trans-activating CRISPR RNA
to form trcrRNA, which mediate the sequence-specific binding and cleavage of
foreign DNA by Caspases [52]. This CRISPR/Cas system can presumably be
redesigned to cleave any DNA sequence of interest by simply modifying the crRNA
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[52]. A concern with the use of CRISPR/Cas system is the potential for off-site
effects. More studies are required to evaluate whether this method affords the
necessary level of recognition selectivity required for targeting a single specific site
in more complex genomes [52].
ZFNs were the initial group of synthetic nucleases tested, and therefore are the
most studied to date. These synthetic nucleases are designed in pairs, with each
ZFN binding one strand of the DNA double-helix at a specific sequenced
determined by zinc-finger protein (ZFP) recognition motifs [54-58]. As reviewed in
Urnov et.al., these ZFPs contain a tandem assembly of Cys2-His2 fingers, each
capable of recognizing 3bp of DNA. A series of ZFPs are linked together to provide
for longer recognition sequences, typically ranging from 9bp on each strand (total
of 18bp per cleavage site) to 18bp (total of 36bp per cleavage site), thus providing
specificity for cleavage of unique sequences on the genome [54-58].
Several groups have reported successful targeting of human cells using ZFNs,
in some cases introducing gene modifications to knock out a gene, and in other
cases, correcting disease-causing mutations by targeted substitution or gene
addition [47, 59-61]. Following a gene knock-out study in primary human T-cells,
Perez et.al. reported successful targeting of the human CCR5 locus using ZFNs,
and showed, by DNA sequencing analysis, that ZFNs are quite specific for their
target. Only one other locus – the closely related CCR2 gene - was cleaved by the
nucleases at a significant level, albeit still at much lower frequency than the target
CCR5 locus [59]. Holt et.al. demonstrated this same locus could be targeted in
human CD34+ HSPCs using ZFNs, and that the engraftment and differentiation
13

potential of these cells were not impaired by ZFN activity [62]. Furthermore, Moehle
et.al.

demonstrated

high

efficiency

site-specific

integration

of

long

extrachromosomal DNA donors via homology-directed repair in cells stimulated by
ZFN-induced DSB, and, through this, established proof-of-principle for gene
addition as a feasible approach for correction of mutation [47].

1.5 Genome Editing in induced pluripotent stem cells (iPSC)
The

ability to

genetically reprogram

somatic

cells

to a

pluripotent,

undifferentiated state using specific factors was first described by Shinya
Yamanaka’s group in 2006 from studies in mouse fibroblasts [63]. The following
year, both Shinya Yamanaka and James A. Thompson’s group published reports
describing that a combination of four factors was capable of inducing the
reprogramming of human fibroblasts to pluripotent cells [64,120]. These
reprogrammed cells, named induced pluripotent stem cells (iPSC), had embryoniccell (ESC)-like morphology, and expressed the canonical ESC-specific cell surface
markers. They also retained normal karyotype and demonstrated normal ESC-like
pluripotent function by generating [64].
The advent of reprogramming technology broadened the opportunities for
regenerative medicine and drug discovery. The possibility of deriving any tissue of
interest from iPSC became an important aspect that inspired many scientists to look
at these cells as a model for disease studies, especially in the case of rare
disorders, for which patient samples are difficult to obtain. Genome editing in iPSC
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quickly became an attractive strategy for therapies for monogenic diseases, such as
WAS and other hematological disorders [65-68]. Many studies have coupled the
iPSC technology with the use of tools for precise gene modification to generate
reporter cell lines, correct disease-causing mutations, generate gene knock-out
models, among many other applications, illustrating the vast utility of iPSC [60, 6973]. Zou et.al. reported in 2011 the generation of iPSC from X-linked Chronic
Granulomatous Disease (X-CGD) patient mesenchymal stem cells (MSC), and the
subsequent genetic correction of these cells by ZFN-mediated HDR with a
homologous DNA donor. They further differentiated the corrected cells into mature
neutrophils and demonstrated restoration of normal function [60].
Similar to the work done for X-CGD correction, we generated iPSC from a
WAS-patient’s skin fibroblasts and corrected the defect by ZFN-mediated targeted
gene addition in the endogenous WAS locus. Following in vitro differentiation of
corrected WAS iPS (cWAS) into hematopoietic progenitor cells, we were able to
demonstrate restoration of WASp expression, which correlated with functional
restoration in Natural Killer (NK) cells derived from the corrected progenitors (Figure
2).
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Figure 2: Schematic illustrating overall goal of gene correction project.
project
Reprogramming of WAS-patient
patient fibroblasts followed by the subsequent correction of
disease-causing
causing mutation in iPSC provides a valuable tool for generation of
disease-free
free hematopoietic cells.
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CHAPTER 2: MATERIALS AND METHODS

2.1 Cell lines and culture
Skin fibroblasts from a WAS patient were obtained through Coriell Cell
Repositories (Coriell # GM01598). WAS-fibroblasts and mouse embryonic
fibroblasts (MEF; CF-1 mouse strain, Charles River) were maintained in DMEM
supplemented with 10% fetal bovine serum (FBS), 2mM L-glutamine, and 2mM
non-essential amino acids (NEAA), all from Invitrogen/Life Technologies.
Human embryonic stem cells (WA09) were maintained in hESC medium
conditions, as outlined by the National Stem Cell Bank protocol SOP-CC-001C.
Cells were maintained in DMEM-F12 (Invitrogen) supplemented with 20% Knockout Serum Replacer (Invitrogen), 2mM L-glutamine (Invitrogen), 2mM NEAA
(Invitrogen), 4ng/mL basic fibroblast growth factor (bFGF; Invitrogen), and 55µM 2mercaptoethanol (Sigma). Medium changes occurred daily. WAS iPSC and cWAS
iPSC cell lines were generated in our laboratory, and were cultured in the same
hESC medium, but instead with 40ng/mL bFGF, with daily medium changes. All
cells were cultured under humidified conditions at 37°C and 5% CO2 unless
otherwise specified.
Both hESC and iPSC cells were passaged in clumps every 5-6 days, by first
removing medium and washing twice with DPBS (+ Calcium,+ Magnesium;
Invitrogen). Initial mild chemical detachment of colonies was induced by brief
incubation (3-5 minutes) with Collagenase Type IV (Invitrogen), followed by two
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washes with dPBS. Using a 5mL glass pipette tip, the well was scraped in vertical
and horizontal motions to cut colonies into pieces, and collected by gentle pipetting.
Cells were typically split at 1:6 to 1:12 ratio, and were subsequently plated onto
0.1%-gelatin (Sigma) coated 6-well cell culture plates (BD Biosciences) pre-seeded
with approximately 2x105 irradiated MEF (iMEF) feeders per well.
When performing single-cell adaptation, WA09 hESC and iPSC cells were first
washed twice with DPBS, and 1mL of pre-warmed TrypLE reagent (Invitrogen) was
added to each well, followed by incubation at 37°C for 2 minutes. After thoroughly
removing TrypLE by carefully aspirating from the side of the well, we added 1mL of
hESC or iPSC medium, collected cells in a 50-mL conical vial, and filtered through a
70µm cell strainer (BD Biosciences). Cells were then plated onto 6-well plates preseeded with approximately 1.3x105 iMEF per well. For the first two-three passages
under single-cell dissociation, cells were plated at 1:1 to 1:2 ratio. Later passages
were plated at 1:3 to1:6 ratios. Cells were passaged by this method 4-5 times
before considered adapted to single-cell dissociation. Once a line was adapted,
cells were expanded and cryopreserved in individual vials. Each adapted line was
cultured for a maximum of 12-14 passages.
Murine bone-marrow stroma OP9 cells (provided to us by Naioki Nakayama),
and OP9-DL1 cells (provided by Bart Vandekerckhove) were cultured in alpha-MEM
medium supplemented with 20% FBS, 2mM L-glutamine, and 1X PennicillinStreptomycin (P/S; Invitrogen). Inactivation of these feeder cells, when necessary,
was done by 3-hour incubation with 15µg/mL mitomycin C at 37°C with 5% CO2.
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2.2 Derivation of WAS induced pluripotent stem cells (WAS-iPSC)
Patient skin fibroblasts were reprogrammed using pMXs-based retroviruses
expressing the reprogramming factors OCT4, SOX2, KLF4, CMYC, AND NANOG.
These reagents were provided by K. Plath and obtained through Addgene. For
generation of pMXs-GFP construct, we obtained the ORF of eGFP by PCR
amplification of CCR5-PGK-GFP construct provided by Michael Holmes (Sangamo
Biosciences). Amplification introduced two novel enzyme sites – NotI and EcoRI –
flanking the gene. The amplicon was then added to the pMXs vector backbone by
directional cloning using NotI and EcoRI. For packaging the viruses, we adopted
the protocol form Park and Daley [74] for VSV-G pseudotyped retroviral vectors.
Two 150mm-plates were each seeded with approximately 7 million Plat-GFP
Retrovirus Packaging Cell line
including the GFP control.

(Cell Biolabs, Inc.) for each vector construct,

The following day, each plate was transfected with

6.25µg of the pMX retroviral vector backbone and 0.9µg of pCMV-VSV-G plasmid
(obtained through Addgene). Each 15mm-plate of cells was maintained in 30mL of
medium (DMEM, 10% FBS, 10µg/mL of Bastidcidin) containing 50µL of Fugene 6.
Supernatant containing the virus was harvested 48 hours after transfection, and
filtered through a 0.45µm filter into a polyallomer centrifuge tube. Material was
centrifuged at 260000 rpm for 2 hrs in an ultracentrifuge (Beckman Coulter). Viral
pellets were re-suspended in 600µL of DMEM-F12 and 100X concentrations of
virus were generated. Infectious virus titer was determined by titration on human
primary fibroblasts with pMXs-GFP virus, followed by flow-cytometric analysis for
GFP expression.
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For the reprogramming of patient skin fibroblasts, 105 cells were plated onto
each well of a 6-well tissue culture plate on day 0. On the following two days, cells
were transduced with the 5 reprogramming factors (OCT4, SOX2, KLF4, C-MYC,
AND NANOG) by spinfection at a multiplicity of infection of 21.5 virus particles per
cell, in fibroblast medium containing protamine sulfate (10µg/mL). Approximately
2.5 days after initial transduction, cells were trypsinized and replated at a 1:1 ratio
onto gelatin-coated plates seeded with iMEF. The following day, the medium was
removed and hESC medium containing 40ng/mL bFGF was added, initiating
pluripotent stem cell culture conditions. Starting at day 12 of culture, hESC medium
pre-conditioned on iMEFs was used, and medium changes occurred daily. At
approximately day 16 post-transduction, individual iPSC-like colonies began to
emerge, and initial detection was done based on morphology. Live-cell staining for
known pluripotent stem cell surface marker - TRA-1-60 – was done (anti-TRA-1-60
mouse IgM monoclonal antibody, Stemgent, 1:200 dilution, followed by Alexa488conjugated anti-mouse IgM seconday antibody, 1:250 dilution; both from Invitrogen)
and iPSC colonies were confirmed. Each iPSC clone was subsequently cut into
smaller fragments with a glass, end-closed pipette, and transferred – one colony per
well - into a 12-well tissue culture plate pre-seeded with iMEF. Plating medium
used was hESC medium supplemented with 10µg Y-27632 (Alexis Biochemicals).
Once plated, cells were allowed to expand, and upon successful expansion, they
were further passaged in a 1:2 to 1:4 ratio in subsequent passages. Once clones
were established, they were characterized, expanded, and cryopreserved.
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2.3 Characterization of iPSC
Each clone was analyzed first for expression of known pluripotency markers.
Expression of TRA-1-81 surface marker was analyzed by live-cell immunostaining
(anti-TRA-1-81 mouse IgM, 1:200 dilution, Millipore). Moreover, following Wicell
protocol (SOP-CH-102B) co-expression of SSEA-4 surface protein and OCT4
transcription factor by flow cytometry was assessed on BD LSRII running BD
FACSDiva software (Becton Dickinson). We considered detection of ≥90%
OCT4+SSEA4+ cells to be a population of pluripotent cells with minimal
spontaneous differentiation. Alkaline phosphatase activity was assessed by
VECTASTAIN ABC-AP Kit (Vector laboratories) by first fixing iPSC with 2%
paraformaldehyde in DBPS for approximately 30 minutes. Following incubation,
paraformaldehyde was removed and the substrate solution 123 was added to each
well. Cells were allowed to incubate in the substrate solution in the dark, as per
manufacturer protocol. Following a 5-minute wash with DBPS containing 0.1%
Tween-20, cells were observed under microscoscope. Karyotype analysis of WAS
iPSC was performed at Texas Children’s Hospital Clinical and Research
Cytogenetic Laboratory where approximately 20 metaphase cells were analyzed per
line.
Pluripotent function of each iPSC line was assessed by teratoma formation
assay. iPSC were cultured on 30% Matrigel with daily medium changes using
mTESR (Stem Cell Technologies) to remove residual iMEF. Approximately 2-3
million iPSC were injected into the kidney capsule or the testis of six-week old Fox
Chase SCID beige mice (Charles River), and monitored weekly for emergence of
21

tumor. A total of 3 mice were prepared for each cell line. Tumors were removed 6-8
weeks post injection, paraffin-embedded, and prepared for histological analysis by
hematoxylin adeosin (Applied Stem Cell Inc.).
Pluripotency gene expression was assessed by quantitative RT-PCR. The goal
of this analysis was to confirm silencing of retroviral transgenes used in the process
of reprogramming. Total RNA was isolated from iPSC and control hESC WA09
(RNeasy kit, Qiagen), and synthesized cDNA by reverse transcription using
Improm-II Reverse Transcription System (Promega). The levels of expression of
pluripotency genes were assessed by SYBR Green incorporation. By using specific
primers we were able to distinguish endogenous gene expression from total gene
expression for each of the reprogramming factors (each primer set included one
primer designed to bind sequences that include the 3’UTR) (Table1).
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Table 1: List of Primers used for pluripotency gene expression analysis.
Primers used for qRT-PCR
PCR analysis of expression of pluripotency
pluripotency-associated
associated genes
in iPSCs generated from patient fibroblasts as well as WA09 hESC normal control.
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RT-PCR analysis was performed in duplicates for each cell line using an ABI7900
instrument. Expression levels were normalized to that of house-keeping gene
GAPDH, and the profile obtained for iPSC lines was compared to the one obtained
for the WA09 hESC control cell line.
Southern Blot analysis of genomic DNA from WAS iPSC and cWAS iPSC was
performed with the goal to verify the number of donor integrations present in the
targeted-corrected cWAS iPSC. Genomic DNA was first digested with PvuII and
ScaI restriction enzymes. A 2.3kb long probe encompassing the pgk-Puro-TK
selection cassette was used to detect integration sites in puromycin-resistant
clones. We expected the probe would hybridize with a 3.8kb long genomic DNA
band that resulted from initial enzyme digestion.

2.4 Assessment of ZFN activity
Two pairs of zinc-finger nucleases targeting the WAS gene – S1 and S4 - were
engineered by Sangamo Biosciences, and provided to us as a gift through a
collaboration. S1 ZFN plasmids (pVAX-C2A-3FN-Fok11914 and pVAX-N2A-3FN
11916-Fok) and S4 ZFN plasmids (pVax15755 and pVax15724)) were first tested in
K562 erythroleukemia cells. Using Amaxa Nucleofection cell line kit V (Lonza), ZFN
expression plasmids were delivered to K562 cells as per protocol instructions, at
doses ranging from 1ug to 5µg per ZFN (2µg to 10µ total ZFN plasmid). Following
manufacturer’s protocol, we used Nucleofection kit V (Lonza) and electroporated
1x106 K562 cells per reaction. Immediately following electroporation, cells were
24

gently transferred from cuvette to a 6-well tissue culture plate containing K562
medium – PRMI1640 (Hyclone, Fisher Scientific), 10%FBS (Hyclone, Fisher
Scientific), 2mM L-glutamine (Invitrogen), 1X P/S (Invitrogen). Cells were cultured
for 7 days in incubator at 37°C, 5% CO2.

Cell proliferation was assessed by

counting every 2 days in a hemacytometer. Cell viability was evaluated by Trypan
Blue staining (Life Technologies).
In experiments with iPSC we transfected 2x106 dissociated cells by Amaxa
Nucleofection (Stem cell kit 1, Lonza). ZFN expression plamids or in situ generated
RNA were delivered. In order to generate RNA for each ZFN, 1µg of plasmid DNA
was first linearized by XbaI digestion. Following linearization, capped RNA was
synthesized using MessageMAXTMT7 ARCA-Capped Message Transcription Kit
(CellScript, Inc.) as per protocol. This product was then treated with DNaseI, and
subsequently, a poly(A) tail was added using Poly(A) Polymerase Tailing Kit
(Epicentre). This material was purified by MegaClear Kit (Ambion), and analyzed on
Agilent Bioanalyzer for assessment of size, concentration, and quality.
Following transfection, cells were plated in a gelatin-coated well of a 6-well
plate pre-seeded with approximately 2.5x106 iMEF per well, and cultured in iPSC
medium - DMEM-F12 (Invitrogen) supplemented with 20% Knock-out Serum
Replacer (Invitrogen), 2mM L-glutamine (Invitrogen), 2mM NEAA (Invitrogen), 40
ng/mL basic fibroblast growth factor (bFGF; Invitrogen), 55µM 2-mercaptoethanol
(Sigma), and supplemented with rock inhibitor Y-27632 (Alexis Biochemicals) only
for the first day. Medium was changed daily. Approximately 3-5 days from initial
transfection, we harvested DNA from bulk culture, and a 253-bp region flanking the
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ZFN cleavage site (Table
Table 2
2)) was amplified by PCR ( AccuPrime High fidelity taq
polymerease, Invitrogen).

Table 2: List of Primers..
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ZFN activity in pools of cells was determined by using the CEL-1 /Surveyor
nuclease assay (Transgenomics) [59, 61]. CEL-1 recognizes allelic mismatches
resulting from the rapid but imperfect Non-Homologous End-Joining (NHEJ)mediated repair of double-strand break induced by ZFN (Figure 3).
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Figure 3: Schematic illustrating method applied for determination of ZFN
activity analysis. This schematic describes ZFN activity when delivered without
donor molecule. Subsequent to cleavage, dsDNA break is repaired by NHEJ, and
an indirect measure of ZFN activity is obtained by treatment of DNA with CEL-1
nuclease.

28

PCR amplification of bulk-transfected cells generates a mixture of wild-type
(WT) and mutant amplicons. By denaturing and slowly reannealing this product
(95°C incubation for 10 minutes; cool to 85°C at -2°C/sec, and cool to 25°C at 1°C/sec), homoduplexes originate (either from two WT strands or two mutant
strands) as well as heteroduplexes (formed when a WT strand reanneals to a
mutant strand), in which case a DNA “bubble” is formed as a consequence of basepair mismatches. These mismatch sites are cleaved by CEL-1, and subsequently
resolved on a 10% polyacrylamide gel. Through densitrometry quantitation using
Sybr Gold (Life Technologies) we were able to compare the intensity of the cleaved
heteroduplexes to that of the parental band and determine the level of CEL-1
activity, which was calculated using the equation: %CEL-1= (1-(√parental
fraction))x100. This value, in turn, is an indirect measure of the frequency of
endogenous target sequences that underwent NHEJ repair subsequent to ZFNmediated cleavage.

2.5 Generation of Donor template
We initially amplified from wild-type K562 cells a 1.6kb-long region of WAS
sequences encompassing exons 1 and 2, and spanning the ZFN-cleavage site in
intron 1. These sequences were cloned into the pSC-B–amp/kan vector (Agilent
Technologies), generating our WAS-homology donor arms. Subsequently, by sitedirected mutagenesis, we introduced an NsiI endonuclease site in intron 1, near the
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ZFN cleavage site, leaving 751bp of WAS-homology sequences to the right of the
enzyme site, and 815bp to the left (Figure 4).
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Figure 4: Generation of donor homology arms. Approximately 1.6kb of WAS
sequences flanking the ZFN cleavage site were used to generate the homology
arms necessary for HDR-mediated integration into the WAS locus.
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For generation of our first donor, we cloned a 43-bp oligonucleotide sequence
containing a BamHI enzyme site directly into the NsiI site of pSC-B homology donor
vector. The resulting construct was named “patch donor”.

For our next donor

molecule, we used PCR amplification to extract the sequences for PGK-GFP-pA
from the CCR5-Patch-hPGK-GFP-pA-DonorTOPO plasmid obtained from our
collaborators at Sangamo Biosciences. Both the forward and reverse primers
contained NsiI sites, and amplicon was cloned by ligation into the NsiI site in the
pSCB plasmid. The resulting plasmid contained PGK-GFP-pA sequences flanked
by WAS-homology arms.
In order to build our correction donor, we purchased a vector encoding the
WAS cDNA sequences. By site-directed mutagenesis, we introduced a base-pair
change (C→A) at position 995 in exon 10 (QuickChange Lightening Site-Directed
Mutagenesis kit, Agilent Technologies). We then extracted exons 2-12 sequences
using custom-designed fusion primers containing splice acceptor sequences on the
5’→3’ forward primer (table 2). The reverse primer included WAS exon 12
sequences and approximately half of the 2A sequences. A second set of primers
was used to amplify eGFP from our PGK-GFP donor plasmid (table 2). The forward
primer in this set contained the remaining sequences necessary for completion of
the 2A peptide sequences linking WAS and GFP (table 2). These amplicons were
generated in such a way as to work as “puzzle pieces” that fit together in the order
WAS-2A-GFP. We cloned the two pieces in one single reaction by In-Fusion cloning
(In-Fusion® HD Cloning Kit, Clontech Laboratories) into the donor homology plasmid
vector. Our next step was to add the selection cassette to the WAS-2A-GFP donor.
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Using In-Fusion primers, we PCR-amplified the loxP-pgk-PuroTK-loxP sequences
from pPthc-Oct3/4 plasmid (received from Dr. Naioki Nakayama). This cassette
allowed us to include the puromycin resistance gene, as well as the thymidine
kinase “suicide” gene for negative selection. This double selection feature was
instrumental in obtaining our final targeted clones. We cloned the selection cassette
in the

SexAI enzyme site using In-Fusion technology (In-Fusion® HD Cloning,

Clontech Laboratories).

2.6 Target Integration in WAS iPSC
We had previously determined that delivery of 2µg of each ZFN in the form of
RNA was sufficient to induce good level of activity without cytotoxic side-effects.
ZFN and/or donor plasmid were delivered by Amaxa Nucleofection using the
Human Stem Cell Nucleofector Kit 1 (Lonza). For each reaction, 2x106 iPSC were
first dissociated to single-cell suspension by Accutase treatment for 2-3 minutes at
37°C (STEMCELL Technologies). This brief treatment resulted in most iMEF
detaching from the well, leaving the iPSC still slightly attached to the plate. This
facilitated removal of iMEF during careful aspiration of Accutase. We then
mechanically dissociated iPSC by adding PBS and gently pipetting. Cells were
subsequently centrifuged in 1.5mL micotubes at 200g for 5 minutes. Following
removal of supernatant, cell pellets were resuspended in 100µL of nucleofector
solution (provided in the kit). Each cells suspension was then mixed with ZFN and
donor reagents. For each experiment, a minimum of 3 samples were prepared: 1)
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ZFN-only control (2µg of ZFN-RNA and 2x106 iPSC), 2) Donor only (4µg or 8µg of
donor plasmid), and 3) ZFN+Donor (2µg of ZFN-RNA and 4µg or 8µg of donor
plasmid). Each mixture was placed in a cuvette and electroporated in nucleofector,
under Amaxa program A23. Following nucleofection, we used 500µL of iPSC
medium supplemented with 10µM Y-27632 to gently transfer cells from cuvette to a
gelatin-coated 6-well tissue culture plate pre-seeded with puromycin-resistant iMEF.
The contents of each cuvette were divided into 2 wells. Starting on the following
day, culture medium was changed daily. Puromycin selection (by feeding cells with
medium containing 0.5µg/mL of puromycin) started at day 4 post transfection, and
approximately 2-5 days later, puromycin-resistant colonies were mechanically
picked and transferred to a new 6-well plate for expansion (about 3 to 4 additional
passages under puromycin selection).
Following expansion in puromycin-containing medium, each remaining clone
was analyzed by target-integration PCR (TI-PCR) with primers spanning the
integration site (Table 2). In order to ensure successful amplificatioin of a long
product (if targeted integration occurred), we used the Expand Long Template PCR
system (Roche Applied Science), as per manufacturer protocol. PCR product was
resolved by agarose gel electrophoresis.

2.7 Generation of hematopoietic progenitor cells from iPSC
We used a spin embryoid body (EB)/ OP9 co-culture method for generation of
CD34+CD43+ hematopoietic progenitor cells from pluripotent stem cell lines: WAS,
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cWAS, WA01, and WA09. For EB generation, we slightly adapted the Ng et.al.
protocol [75]. EBs were generated from single-cell adapted iPSC in expansion
phase. All cultures had undergone 6 to 8 passages under TrypLE selection. When
using cryopreserved cells, we first thawed and cultured cells on low-density iMEF –
coated 6 well plates for two passages prior to experiment.
On the day of experiment, we washed cells twice with DPBS (Invitrogen). We
then added 1mL of pre-warmed TrypLE (Invitrogen) into each well and incubated at
37°C for 2 minutes. This short incubation was sufficient to dissociate the colonies
and detach iMEF feeders. Following incubation, we carefully removed TrypLE, and
with it most of the iMEF. We added 1mL of hESC medium containing 10µM Y27632, collected cells by gentle pipetting, and filtered cell solution through a 70µm
strainer (BD Biosciences). We counted cells, and aliquotted the necessary number
of cells for preparing 4 to 6 96-well plates containing 1 spin EB per well – typically
5000 WA09 cells per EB, and 7000 WAS iPSC or cWAS iPSC per EB. Once the
appropriate number of cells was obtained, vials were centrifuged at 430g for 3
minutes at 4°C.

Supernatant was removed, and cells were resuspended in

hematopoietic differentiation medium – STEMdiff APEL medium

(STEM CELL

Technologies) supplemented with Stem Cell Factor (SCF; Peprotech), Vascular
Endothelial Growth Factor (VEGF; Peprotech), Bone Morphogenic Protein 4 (BMP4;
Peprotech), and Y-27632 (Alexis Biochemicals). Table 3 lists the specific amounts
of each of these factors required for our iPSC and WA09 hESC lines.
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Table 3: Optimal cell number and cytokine conditions for hematopoietic
differentiation. Both cell number and cytokine levels were empirically determined
for each cell line. Table shows optimal conditions used in hematopoietic
differentiation experiments.

36

Using a multichannel pipette and a sterile reservoir, we quickly dispensed
100µL of solution containing the appropriate number of cells into each well of a lowattachment U-bottom 96-well plate (BD Biosciences), such that one EB would be
generated per well. Plates were centrifuged at 480g for 7 minutes, at room
temperature. Following centrifugation, we verified by microscopy that each well
contained the same size cluster of cells centered at the bottom of the well. Plates
were placed in incubator at 37°C with 5%CO2 and remained in culture for 4 to 5
days. Medium was not changed during this time, with the goal to keep EB
undisturbed.
Throughout this initial period in culture, EBs developed significantly, adopting a
compact, three-dimensional spherical structure, and growing in size. Four to five
days after plating, we harvested EBs by carefully pipetting each EB out of the well
using a P1000 pipette. We transferred 16 EBs into each well of a 6-well plate, preseeded with 2x105 mitomycin-C –treated murine OP9 bone marrow stromal cells
per well. Prior to transfer, each well was washed twice with PBS (Hyclone, Thermo
Scientific). EB/OP9 co-culture was maintained for 8 to 9 days in STEMdiff APEL
medium supplemented with SCF, VEGF, and BMP4 as previously described. At day
4 post transfer, we refreshed medium by adding 1mL fresh STEMdiff APEL
containing the three factors and rock inhibitor into each well.
Subsequent to transfer onto OP9 stroma, we observed the EBs quickly
attached to the feeders (typically about 4-6 hours after transfer). On the following 2
to 3 days, EB-generated stromal cells began to spread to the immediate vicinity of
the EB. Between days 3 and 4, we observed the emergence of “bubble-like”
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vesicles expanding outward from the EB, and, inside these structures, hundreds of
small, round, hematopoietic-like cells appeared. Over the next couple of days, more
of these cells emerged, and they were released into the stroma. We hypothesized
this event indicated the start of hematopoietic differentiation. In order to better
capture this dynamic process, we observed one well for 2 days (from day 4 to day
5), by live imaging. Time lapse images were acquired at 20-minute intervals with an
Andor IXon3 885 EMCCD camera (Andor) on an Olympus IX-81 (Olympus)
microscope fitted with a microscope enclosure (Precision Plastics) maintained at
37°C with 5% CO2. A final compilation of images resulted in a movie recapitulating
the emergence and progression of hematopoietic cell development in the EB/OP9
co-culture.
On day 8 to 9 post transfer, we observed a lot of hematopoietic-like cells
floating in culture, and clusters of these cells spread throughout the well. We
harvested supernatant, and added 1mL pre-warmed TrypLE into each well. Plates
were incubated for 3 minutes, and EBs were collected by adding 1mL of STEMdiff
APEL medium into each well, and pipetting vigorously. Subsequently, EBs were
pooled and transferred into a 50-mL conical vial (BD Biosciences). We mechanically
dissociated EBs by repeatedly passing them through first a 20-gauge needle (3 to 4
times), followed by a 25-gauge needle in a 5-mL syringe (3 to 4 times). Once EB
were completely dissociated, solution was filtered through a 70µM cell strainer, and
filtered cells were centrifuged at 350g for 5 minutes. We subsequently washed cells
once with PBS, resuspended in PBS, and filtered through a 45µM cell strainer, and
counted by Trypan Blue exclusion method.
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2.8 Flow Cytometric Isolation of CD34+CD43+ hematopoietic progenitor cells
Progenitors derived from each line – WAS iPSC, cWAS iPSC, and WA09
hESC– were collected after PBS wash, and stained, following

manufacturer’s

protocol, for known hematopoietic surface markers CD34 (Allophycocyaninconjugated mouse IgG1,κ clone 8G12, BD Biosciences), CD43 (Brilliant Violet 421conjugated mouse IgG1,κ clone 1G10, BD Horizon), and CD45 (Phycoerythrinconjugated mouse IgG1,κ clone HI30, BD Pharmingen). Respective isotype controls
were also generated for each fluorophore used in the panel. Samples were
incubated on ice for 30 minutes, and subsequently washed twice with 1mL FACS
buffer (PBS, 2%FBS). After second wash, samples were resuspended in 400µL of
FACS buffer per 1x106 cells. Flow cytometric analysis was performed using
BDFACS Aria II instrument (BD Biosciences), and we sorted the CD34+CD43+
hematopoietic progenitor population from each cell line. We observed that, for
cWAS-derived progenitors, the sorted population expressed GFP.

2.9

Flow

Cytometric

Analysis

of

WASp

expression

in

CD34+CD43+

hematopoietic progenitor cells
In order to allow for cell receptor turnover to eliminate from the cell surface
residual antibodies used for sorting, we cultured sorted CD34+CD43+ hematopoietic
progenitor cells for approximately 36 hours prior to immunostaining. During this
time, cells were maintained in STEMdiff APEL medium supplemented with SCF,
VEGF, and BMP4, as described in the previous section.
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WASp is an intracellular protein, and, in order to assess WASp expression in
sorted

CD34+CD43+

hematopoietic

progenitor

cells,

we

first

centrifuged

approximately 5x105 cells from each line, for each condition. We aspirated
supernatant and vortexed each tube to dislodge the pellets. Cells were
resuspended in 100µL of fixation medium (Reagent A, Invitrogen Fix & Perm kit)
and incubated at room temperature for 15 minutes. Following incubation, cells were
washed with 2mL of PBS supplemented with 5%FBS, and subsequently centrifuged
at 300g for 5 minutes. Again cell pellets were dislodged by vortexing, and
resuspended in 100µL (final volume) of permeabilization medium (Reagent B,
Invitrogen Fix & Perm kit) containing either 20µL mouse monoclonal anti-WASpAPC B-9 IgG2a antibody (Santa Cruz Biotechnology), or the respective isotype
control. Following 20-minute incubation at room temperature, cells were washed
with PBS/5%FBS and re-suspended in 300µL of FACS buffer. Cells were analyzed
on BDFACS Aria II instrument (BD Biosciences).

2.10 Colony-Forming Assay
Through flow cytometry sorting, we obtained total CD34+ cells from day 14
differentiation of WAS, CWAS, and WA09. We centrifuged 1.5x105 cells per line at
350g for 5 minutes. We resuspended each cell pellet in 1.5mL of PBS. To each vial
of cell solution, we added hSCF (100ng/mL), hFlt3L (100ng/mL), hMGDF/TPO
(100ng/mL), hIL-6 (10ng/mL), hIL-3 (10ng/mL), hGM-CSF (10ng/mL), hG-CSF
(10ng/mL), and EPO (4units/mL) (all from Peprotech).
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In a 50-mL falcon tube, we prepared colony assay medium by mixing together
Methyl Cellulose (STEMCELL Technologies) + 1% BSA (Sigma) + 30% FBS
(Hyclone, Thermo Scientific) using a 5mL syringe. We then added each cell-growth
factor mixture to 4.5mL of methyl Cellulose colony assay medium, and vortexed
vigorously to mix the contents well. Using a clean 5mL syringe, we transferred
approximately 1.5mL of mixture into each of 3 35mm sterile tissue culture plates.
Subsequently, plates were incubated in humidifier chamber at 37°C with 5% CO2 for
14 days. We performed two experiments, each in triplicate.

2.11 Reverse Transcription PCR (RT-PCR) analysis
We performed RT-PCR analysis of RNA isolated from sorted CD34+CD43+
hematopoietic progenitor cells for detection of WASp mRNA and GFP mRNA in the
cells derived from cWAS iPSC. First, we isolated total RNA from iPSC and control
hESC WA09 (RNeasy kit, Qiagen) lines, and synthesized cDNA by reverse
transcription using Improm-II Reverse Transcription System (Promega). We
quantified RNA in a Nanodrop spectrophotometer. Approximately 150ng of cDNA
was added into a PCR reaction for specific amplification of WAS mRNA using
primers binding to exon 9 (forward primer) and the exon junctions between exons
10 and 11 (Table 2), yielding a 445bp-long amplicon. For detection of GFP mRNA,
we seeded approximately 150ng of cDNA into each PCR reaction and using primers
binding the exon 11-12 junction of the WAS gene and GFP, yielding a 613-bp long
amplicon. All RT-PCR reactions were performed using Platinum Taq High Fidelity
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Polymerase (Invitrogen) utilizing 1X Enhancer (Invitrogen) and, in both cases, cDNA
was amplified for 30 cycles, and then subsequently resolved by agarose gel
electrophoresis.

Negative-control

reactions

were

performed

using

material

generated in a minus-RT reverse transcription reaction (RNA material which did not
undergo reverse-transcription due to absence of Reverse Transcriptase enzyme in
the reaction). In the case of GFP mRNA analysis, DNA isolated from cWAS iPSC
was used as a positive control for amplification.
Subsequent to PCR-amplification, material generated for analysis of WASp
mRNA was purified by a spin-column system (NucleoSpin® Gel and PCR CleanUp, Clontech) and submitted for Sanger sequencing analysis to LoneStar
Sequencing (Houston, TX). We utilized the same forward and reverse PCR primers
for bi-direction sequencing of purified material. We analyzed sequencing results
using Lasergene SeqMan analysis software.

2.12 Generation of Natural Killer (NK) cells
Immediately following flow cytometric analysis and cell sorting, we initiated NK
differentiation of CD34+CD43+ progenitors derived from each of our lines – WAS,
cWAS, and WA09. In order to accomplish that, two days prior to sorting, we seeded
24-well plates (BD Biosciences) with 5x104 live OP9-DL1 murine stromal cells that
express the Notch ligand Delta –like 1. Cells were incubated overnight at 37°C with
5% CO2 in alpha-MEM medium supplemented with 20% FBS, 2mM L-glutamine,
and 1X Pennicillin-Streptomycin (P/S; Invitrogen).
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The following day, each well

was washed twice with PBS, and seeded with 3x104 to 5x104 sorted CD34+CD43+
progenitors per well and kept in NK cell differentiation medium containing: 56.6%
DMEM-high glucose, 28.3% HAMS/F12 (Invitrogen), 15% heat-inactivated human
AB serum (Valley Biomedical), 2 mM L-glutamine (Invitrogen), 1 uM βmercaptoethanol (Sigma), 5 ng/mL sodium selenite (Sigma), 50 uM ethanolamine
(MP Biomedicals), 20 mg/L ascorbic acid (Sigma), 1% P/S (Invitrogen), 20 ng/mL
SCF, 20 ng/mL IL-7 (PeproTech), 10 ng/mL IL-15 (PeproTech), 10ng/mL Flt3 ligand
(Flt3L) (PeproTech), and 5 ng/mL IL-3 (first week only) (PeproTech) [76]. Medium
was prepared fresh on the day of experiment. Cells were cultured in this system for
28-32 days, with half-medium changes occurring every 3-4 days. Umbilical cord
blood (UCB)-derived CD34+ cells were plated under the same conditions and used
as NK differentiation control.
NK cells were also generated (unintentionally) as a by-product of a T-cell
differentiation protocol, as described in Timmermans et.al. [77]. Day 12 spin EBs
were first dissociated as previously described [77] and cells were resuspended in
MEM-α medium supplemented with 20% FBS, SCF (10 ng/ml), fms-like tyrosine
kinases 3 receptor (Flt3-L: 5 ng/ml; Peprotech) and rhIL-7 (5 ng/ml; R&D Systems).
Cells were transferred onto subconfluent OP9-DL1 cultures. Every 3 days, medium
was refreshed by half-medium changes, and every 5-7 days, cells were transferred
onto a fresh OP9-DL1 monolayer. Progenitors were kept in this culture system for a
period of 6-weeks.

43

2.13 Flow Cytometric Isolation of NK cells and analysis of NK phenotype
At the end of 28 days of differentiation in OP9-DL1 co-culture, cells were
harvested by removing the supernatant first, followed by brief dissociation in TrypLE
to dislodge hematopoietic cells that remained attached to stroma (500µL of TrypLE
reagent was added into each well, and plates were incubated at 37°C for 2
minutes).

Following TrypLE dissociation, each well was washed twice with NK

differentiation. Cells were collected, filtered through a 70µM strainer, and
centrifuged at 350g for 5 minutes. We aspirated supernatant, resuspended cells in
PBS by vigorous pipetting, and filtered through a 45µM cell strainer. This material
was centrifuged again at 350g for 5 minutes, and cells were finally re-suspended in
FACS buffer. Mature CD45+CD56+ NK cells were phenotyped by flow cytometric
analysis at day 28-30 (CD56-AF647 and CD45-PE antibodies, BD Pharmingen).
Individual reactions for analysis of NK-specific receptors CD16, NKG2D, CD94, and
CD117, were prepared using the following antibodies: CD16-PE, NKG2D-PE,CD94APC, and CD117-PerCP-Cy5.5 (all from BD Biosciences). Analysis was performed
on BDFACS Aria I instrument (BD Biosciences).

2..14 Immunological analysis of NK-cell effector function
In order to detect restoration of proper immune response by NK cells derived in
our differentiation experiments when in the presence of K562 leukemia cells, we
examined the secretion of Inerferon-gamma (IFN-γ) and Tumor-necrosis factor
alpha (TNF-α) when NK cells were co-cultured overnight with K562 at 1:1 effector44

target ratio. Upregulatioin of cytotoxic cytokine levels was analyzed utilizing the
Cytometric Bead Array (CBA) microbead capture system (BD Biosciences).

2.15 Western Blot Analysis for detection of WASp
Approximately 1.5x106 to 3x106 sorted CD34+ progenitor cells or CD56+ NK
cells from each line were collected by centrifugation at 350g for 5 minutes at room
temperature. Supernatant was removed and cells were washed once with PBS.
Following centrifugation and removal of PBS, working on ice, we resuspended cells
in 100µL to 200µL of RIPA buffer containing 1 protease inhibitor cocktail tablet
(cOmplete Protease Inhibitor Cockail tablet, Roche Applied Science) and
transferred cells to a 1.5mL-eppendorf microtube. We cells lysed for 30 to 60
minutes on ice. Following lysis, tubes were spun down at 13,000rpm for 10 minutes
at 4°C. Protein supernatant was subsequently removed, and cell debris discarded in
the pellet. We added 5µL of each lysate to 95µL of dH2O to generate 20x dilutions,
and measured protein concentration by Bradford Colorimentric Assay (Pierce
BCATM Protein Assay Kit, Thermo Scientific). Our standards were generated from
bovine serum albumin (BSA) dilutions as indicated in manufacturer’s protocol (BioRad Protein Assay Standard II).
Each sample was prepared by taking 10µg of total protein and adding 1X
Reducing

agent

(novex

NuPAGE

Sample

Reducing

Buffer

(10X);

Life

Technologies). We then added 1X novex NuPAGE LSD sample buffer (4X) (Life
Technologies) to each sample. Using RIPA buffer, we adjusted the final volume to
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70µL. We pre-washed NuPAGE 7% Tris-Acetate gel (Life Technologies) 3 to 4
times with dH2O to remove gel debris and bubbles. We then placed gel in the
electrophoresis apparatus. After locking it in position, we filled the inner chamber
with 20X Tris-Acetate SDS Running Buffer (Life Technologies) containing 500µL
Antioxidant (Invitrogen NuPAGE) for each 200mL of running buffer. The outer
chamber was filled with 1X Tris-Acetate SDS Running Buffer. We finally loaded
each sample into a well of the gel. We loaded 8µL of protein standard solution
molecular weight marker (Precision Plus Protein Standard, BioRad). We ran the gel
for approximately 1 hour, at 100V for the first 10 to 15 minutes, and 150V for the
remainder of the time).

In order to prepare for gel transfer, we soaked the

nitrocellulose transfer membrane (Amersham Biosciences Hybond-C Extra Pore
size 0.45µm), Whatman filter paper, and sponges in 1X Transfer Buffer (Invitrogen
NuPAGE) containing 10% methanol. We assembled the transfer “sandwich” (using
the soaked sponges, filter paper, and membrane) closed the chamber, and placed it
in the electrophoresis apparatus. We ran transfer for 2.5 hours at 45V, on ice.
Following transfer, we blocked non-specific binding by incubating membrane in
Blotto blocking buffer (5% solution of non-fat milk in Tris-buffered saline, Thermo
Scientific) for 30 minutes at room temperature with gentle shaking. We
subsequently incubated the membrane in a 1:1000 dilution of anti-human WASp
antibody clone 5A5 (mouse monoclonal IgG2a,κ; BD Biosciences) in TBS buffer
overnight at 4°C. On the following day, we washed the membrane with
approximately 10mL of TBS buffer (enough to completely cover membrane) for 7
minutes with gentle shaking. We washed 4 times, for a total of 30 minutes.
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Following the washes, we diluted an HRP-conjugated secondary antibody (antimouse IgG; Cell Signaling Technologies) 1:5000 in blocking buffer, and incubated
membrane in secondary antibody dilution for 1 hour at room temperature on an
orbital shaker. We then washed the membrane with TBS buffer four times, as
described above in this section.
Detection of target protein was obtained by mixing Reagent A (Luminol
Ehancer solution), and Reagent B (Peroxide solution) (both from Amersham ECL
Prime Western Blotting Detection Reagent kit) at a 1:1 ratio to a final volume of
1mL, sufficient to cover the membrane. We then mixed reagents well, and pipette
the solution over the membrane, allowing it to incubate for 1 to 3 minutes. After
draining the excess liquid, we transferred the membrane onto a piece of clear
plastic wrap, and wrapped it carefully, avoiding airl bubbles. We placed the protein
blot side-up on a photo cassette, and exposed negatives (Amersham Hyperfilm)
onto membrane and developed the films to obtain final Western results.

2.16 Comparative Genomic Hybridization Analysis

We isolated DNA from WAS iPSC and cWAS iPSC, and 8ug of each purified
material was sent to WiCell for comparative genomic hybridization and Singlenucleotide polymorphism (SNP) analyses. Samples were analyzed using the Agilent
SurePrint G3 Human Genome CGH+SNP Microarray. This array analysis is
capable of detecting copy number gains and losses, copy neutral aberrations, and
mosaicism. Data analysis was also done by WiCell.
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2.17 Cell preparation and flow cytometric sorting of WASp+ revertant cells

Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque
density gradient (GE Healthcare) for both patient samples and normal controls.
Immediately following isolation, cells were sub-fractionated into distinct lymphocyte
populations by magnetic bead separation (Dynalbeads, Invitrogen).
Cells were initially stained for cell surface antigens using FITC-conjugated antiCD4 antibody and Phycoerythrin (PE)-conjugated anti-CD8 antibody (BD
Biosciences) for T-cells, APC-conjugated anti-CD45RO (BD Biosciences) for
distinguishing between memory and naïve T-cells. Subsequently, cells were
washed, then fixed and permeabilized with Caltag Fix & Perm kit (Invitrogen), and
further stained with anti-hWASP mouse monoclonal antibody (clone B9, Santa
Cruz), or purified mouse IgG for 30 min at 4°C. Stained cells were analyzed and
sorted by FACS Aria flow cytometer and analyzed using DIVA software (Becton
Dickinson). Positive and negative cell populations were obtained by fluorescence
cell sorting.

2.18 DNA Isolation and PCR assay
Sorted cells were lysed by incubation with a detergent solution containing
protein K for 2 hours at 42°C. Following lysis, DNA was amplified using fusion
primers spanning the region of interest. Fusion primers were designed based upon
recommendations from Roche 454 for generation of product suitable for next
generation sequencing. Primer sequences: forward 5’→3’gaggctcagaagaaatcaatg,
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and reverse 5’→3’ agctactggacgttctgga. Each primer carries an identifier sequence
(MID) and an adaptor sequence determined by Roche 454, and selected for each
cell type. Utilizing these primers, each population was amplified in two rounds of 30
cycles each with a unique MID, in order to allow for amplicon origin identification
after sequencing. Appropriate PCR product was confirmed by gel electrophoreises
and purified using Agencourt AmPure XP PCR purification kit (Beckman Coulter).
The integrity of purified PCR was further verified by bioanalysis using the 2100
Bioanalyzer (Agilent Technologies).

2.19 Next-Generation Sequencing
Purified PCR product was submitted to Family Tree DNA in Houston, Texas.
Each amplicon pool was subjected to emulsion PCR and subsequent bi-directional
sequencing using Roche 454 GS Titanium Sequencing kit. Sequences were
obtained and analyzed using Roche GS Amplicon Variant Analyzer software. Since
each lymphocyte population from WAS 4 and WASJ patients were amplified using
primers

carrying

different

multiplex

identifier

(MID)

sequences,

individual

populations were separated based on the presence of said MIDs, as listed in table 4
below.

Analysis was then performed on each population separately, and each

genotypic variant identified was catalogued. The total number of forward and
reverse sequence reads carrying the same variant was also obtained for each
genotypic variant identified, and the percentages of each group of forward and
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reverse reads were obtained. The final percentage was determined by taking the
mean of the individual percentages obtained for forward and reverse reads.
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CHAPTER 3: RESULTS

3.1 Generation and characterization of WAS-patient derived induced
pluripotent stem cells (WAS-iPSC)
We obtained skin fibroblasts from a WAS patient through Coriell Cell
Repositories (Corielle # GM01598). Initial Sanger sequencing analysis identified the
patient’s germ line mutation as an insertion of a G at position 1305 in exon 10 of the
WAS gene.

This insertion leads to a frame-shift at amino acid 424 of WASp,

resulting in an aberrant amino acid sequence throughout the C-terminal VCA
domains of WASp and premature truncation, which is believed to lead to
degradation of protein. This region of the protein contains a common acting
monomer-binding motif and an acidic region which activates the actin-related
protein (Arp2/3) complex known to be a key player in polymerization of G-actin [8].
Thus, the C-terminus of WASp plays a crucial role in WASp-dependent signaling
necessary for proper actin polymerization and cytoskeleton reorganization in
hematopoietic cells, as illustrated in Figure 1.
Using retroviral vector-mediated gene delivery, we transduced WAS fibroblasts
with five transcription factors previously reported to induce reprogramming: OCT4,
SOX2, KLF4, CMYC, AND NANOG [63, 64]. Approximately 2 weeks following
transduction, we observed the emergence of human embryonic stem cell (hESC)like colonies. We isolated and further expanded 11 clones in culture, all of which
continued to display both the morphology and proliferation properties consistent
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with those of hESC. We isolated these cells for characterization. First, we confirmed
cells maintained normal karyotype (Figure 5C) and carried the 1305insG germline
mutation in the WAS locus (Figure 5A). Subsequently, cells were analyzed through
immunofluorescence staining and flow cytometry, and shown to express the
characteristic markers of undifferentiated human pluripotent stem cells -TRA1-81,
SSEA-A and Oct4 - and exhibited alkaline phosphatase activity consistent with
hESC-like phenotype (Figure 5B). Lastly, teratoma formation assays provided final
confirmation of pluripotent function of WAS iPSC (Figure 5).
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Figure 5: WAS iPSC characterization. A. Sequencing analysis shows 1305insG in
WAS iPSC; B. Expression of pluripotent markers, TRA1-81 and SSEA-4 surface
antigens and Oct4 transcription factor, and alkaline phosphatase activity; C.
Karyotype analysis shows normal, male karyotype. D. Teratoma formation assay tissues from all germ layers originated from WAS iPSC demonstrating pluripotent
activity.
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Additionally, we assessed pluripotency gene expression in WAS iPSC by
quantitative reverse-transcription PCR (qRT-PCR), and demonstrated expression
levels in patient-specific iPSC were comparable to those seen in WA09 human
embryonic stem cells (hESC), used as control in this experiment. (Figure 6).
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Figure 6: Expression of pluripotency genes in WAS iPSC compared to normal
WA09 hESC.
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3.2 Analysis and optimization of Zinc-Finger nuclease (ZFN) activity
In order to identify high-efficiency ZFNs for targeting the WAS locus, we
analyzed two sets of ZFN plasmids – S1 ZFN and S4 ZFN – recognizing sequences
in exon 1 and intron 1 respectively. These proprietary reagents were provided to us
as a generous gift through collaboration with Sangamo Biosciences.
We initially tested the efficiency of the WAS-ZFN by delivering the nucleases to
K562 cells by Amaxa electroporation. This erythroleukemia cell line was derived
from a female patient, thus carrying two copies of the WAS gene, one on each Xchromosome [78]. Three days following transfection, we sampled the cultures for
DNA analysis by PCR utilizing primers flanking the cleavage site (Figure 7).
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Figure 7: Assessment of ZFN activity on the WAS locus by CEL-1 assay. A.
Schematic illustrating ZFN cutting sites and amplification strategy for CEL-1
analysis. B. CEL-1 digestion of material derived from K562 cells treated with S1 or
S4 ZF
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Following a denaturation-annealing cycle, the product was digested using CEL1 nuclease for detection of allelic mismatches due to NHEJ error-prone DSB repair,
as previously illustrated in Figure 3. The digested bands were resolved by gel
electrophoresis, and by comparing their relative intensity to that of the parental
band, a measure of CEL1 activity at the mismatch sites was obtained using the
equation: %CEL-1= (1-(√parental fraction))x100 (Figure 7B). This value reflects the
level of ZFN-mediated cleavage that induced NHEJ repair in treated cells [56]. We
continued culture of treated cells for an additional 4 days, and observed signs of
toxicity in S1-treated cells in the subsequent days following ZFN-treatment. Cells
looked unhealthy, lost viability, and did not proliferate as well as S4-treated cells.
S4-treated cells survived and proliferated at the same rate as no-ZFN control cells,
indicating no toxicity due to either intron-targeting by ZFN or potential off-target
effects.

3.3 Targeted Endogenous Integration in K562 cells
Once we established efficient ZFN activity in K562 cells, we proceeded to test
our ability to target the WAS locus in these cells. We chose to move forward with
S4-ZFN, and constructed donor molecules which contained approximately 750bp of
WAS-homologous sequences on either side of the cleavage site. Our first donor
template consisted of only a small 45-bp DNA patch containing a BamHI
endonuclease recognition site (Figure 8).
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Figure 8: Patch Donor DNA construction. A. Sequence of oligonucleotide patch
containing BamHI restriction enzyme site. B. Schematic illustrating strategy for
targeting homologous donor molecule to S4 site on WAS gene.
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This enzyme is not present in the endogenous sequence, thus providing us with
a tool for detection of integration. Using Amaxa nucleofection, we delivered ZFN
and donor template at different doses and identified a combination of ZFN-donor
(2.5µg and 20µg, respectively) that resulted in the highest level of targeted
integration, as assessed by BamHI digestion (Figure 9), with 23% efficiency, as
calculated by the ratio of the sum of fluorescence intensities from both digested
bands over the total (taking into account the base-pair length of each band).
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Figure 9: Detection of Patch donor integration in K562 cells. A. Schematic
illustrating PCR strategy for detection of donor integration. B. BamHI restriction
enzyme digestion of material derived from K562 cells treated with donor and ZFN at
different doses, as outlined above gel image.
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Because the efficiency of homology-directed repair decreases with larger donor
templates [47], we built a 1.6kbp-long GFP reporter construct targeted for insertion
in the endogenous WAS locus. This donor comprised a GFP reporter gene driven
by the human phosphoglycerate kinase (PGK) promoter flanked by the same
homology arms as the previous BamHI donor. We nucleofected K562 cells with
ZFN+donor as well as donor-only to account for any potential off-site integrations
that can occur due to spontaneous DSB. We detected GFP+ cells within 48-72
hours following transfection, and at day 7 we sorted the GFP+ population from both
conditions. We subsequently expanded the sorted cells in culture for a period of
three weeks, and extracted DNA for PCR analysis. As illustrated in Figure 10A,
targeting at the intended site in intron 1 of the WAS gene could be easily identified
by a PCR assay. Utilizing primers placed on the left homologous arm of the donor
molecule (forward primer in schematic), and in the endogenous WAS gene intronic
sequence (reverse primer in schematic), a 3kb-long band indicating successful
targeting at S4 site (as shown in Figure 10B). A smaller band of 1.4kb in size was
also identified, representing the proportion of alleles in which no integration of donor
sequences occurred. We observed targeted endogenous integration in only the
GFP+ cells which received both ZFN and donor, at an efficiency of 30%, as
estimated by densitometry analysis (Figure 10C) in the same manner as calculated
for the BamHI donor integration experiment previously described in this section.
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Figure 10: Targeted endogenous integration of PGK-GFP
GFP donor in K562 cells.
A. Schematic illustrating targeted integration and expected sizes for PCR products.
B. Agarose gel electrophoresis analysis of PCR product showing targeted
integration (3.0kb band) in GFP+ K562 cells treated with ZFN and donor.
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3.4 Targeted Endogenous Integration in WAS-iPSC for correction of WAS
mutations
Unlike other monogenic diseases for which there is only one single causative
mutation, different mutations on the WAS gene can lead to undetectable WASp
expression and thus cause the WAS phenotype observed in patients. No single
mutation has been reported as predominant in patients. Therefore, a correction
approach needs to repair most of the reported mutations [5] in order to be
applicable to most patients. Taking this into account, we built a donor molecule
designed for use with S4-ZFNs with the goal of integration in intron 1 of the WAS
gene. This donor consists of wild-type WAS cDNA sequences for exons 2 through
12 (WAS2-12), thus covering almost all the possible exonic disease-causing
mutations that have been reported. We introduced a silent point-mutation at position
995 of exon 10 sequence by replacing the wild-type cytosine (C) with an adenine
(A). This change modifies the existing XhoI restriction enzyme recognition sequence
(CTC*GAG) to an XbaI recognition sequence (TCTA*GA), while still encoding for
the same amino acid, Arginine. This silent modification gives us a valuable tool for
distinguishing between mutant and corrected mRNA material.
The WAS2-12 cDNA was preceded by splice acceptor sequences and, together,
these were linked to a green-fluorescent protein (GFP) reporter gene via 2A peptide
sequences to generate a bicistronic reporter donor molecule. The 2A sequences
are a short peptide (20 amino acids long) and are derived from a group of virus
named Aphthoviruses, an example of which is the Foot-and-mouth disease virus.
These short peptides have been shown to induce a novel “cleavage” event, by
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acting co-translationally and preventing the formation of a normal peptide bond
between the glycine and the last proline which, in turn, causes the ribosome to skip
to the next codon, and the subsequent cleavage between the glycine and the
proline. This results in the release of discrete protein products in stoichiometric
proportions, with most of the 2A peptide fused to the upstream protein [79, 80].
In order to allow for selection of successfully-targeted iPS clones, we
subsequently cloned in a selection cassette containing a murine phosphoglycerate
kinase (pgk) promoter-driven Puromycin-Thymidine Kinase selection markers. The
repair template along with the selection cassette were flanked by approximately
750bp-long WAS-gene-homology arms on either side, yielding the final homologous
donor molecule utilized for targeted correction in WAS iPSC (Figure 11).
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Figure 11: Donor template for correction of WAS
WAS. Final donor construct,
containing flanking homology arms, corrective WAS sequenc
sequences,
es, GFP reporter gene,
and selection cassette. Marked in blue and red boxes are the enzyme selections
used for initial confirmation of successful cloning.
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We confirmed successful cloning by PCR analysis using the same fusion
primers (initially used for cloning) for the amplification of the insert, and detected 5
clones out of 18 which had the expected insert (Figure 12A). We further evaluated
clones 1, 2, 9, and 10 for correct assembly by digestion with BamHI and NotI
restriction enzymes. Based on the plasmid map we constructed (Figure 11), we
expected each enzyme to cleave the donor plasmid in two separate places, yielding
two digested bands in each case (BamHI→ 2.2kb and 8.8kb; NotI→ 3.7kb, and
7.2kb) (Figure 12B).
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Figure 12: Validation of donor construction by PCR and restriction
endonuclease digestion. A. PCR amplification of insert resulted in detection of 5
potentially correct clones. B. Further assessment by BamHI and NotI restriction
enzyme digestion confirms correct clones.
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We co-delivered S4-ZNFs and the WAS2-12-2A-GFP donor construct to WASiPSC by Amaxa nucleofection. Three days later, DNA was isolated from ZFN-only
control, and ZFN activity was determined to be 16% in iPSC using CEL-1 Assay
(Figure 13A). Following subsequent culture under puromycin selection, the 7
surviving clones were analyzed by Targeted Integration PCR assay (TI-PCR)
utilizing primers placed in the endogenous WAS sequences flanking the donor
homology arms. This analysis revealed 6 clones had the desired integration in
intron 1 of the WAS gene (Figure 13B).
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Figure 13: CEL-1 activity and Targeted endogenous integration in WAS iPSC.
A. ZFN efficiency in WAS iPSC determined by CEL-1 assay. B. Schematic
illustrating PCR strategy for detection of targeted clones. PCR amplification of
puromycin-resistant clones was resolved by gel electrophoreisis and shows the
intended targeting at the WAS locus in 6 out of 7 clones.
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In a control experiment, we delivered ZFNs only to iPSC, and determined
cleavage efficiency by CEL-1 assay to be 16% (Figure 13A). Based on clone
stability in culture over several passages (i.e. retaining undifferentiated hESC-like
morphology), we selected clone 5 for further characterization. In order to confirm
integration of our transgene occurred only once in the cellular genome, and at the
intended site, we performed Southern Blot analysis of cWAS clone 5. By digesting
DNA material from targeted and mutant iPSCs with enzymes (PvuII and ScaI) which
cleaved in a pattern that allowed for detection of on and off-site integrations, the
results showed only the desired WAS-intron 1 integration was present (Figure 14).
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Figure 14: Southern Blot analysis of targeted WAS iPSC clone (cWAS).
(cWAS)
Schematic illustrates strategy used for detection of the intended integration on the
WAS gene, as well as potential off
off-site integrations.
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Both WAS mutant and corrected iPSC lines were evaluated by comparative
genomic hybridization array (array CGH) analysis for the presence of potentially
deleterious genetic changes. This analysis resulted in detection of a total of 32
changes. Of these, 25 were shared between the mutant and corrected lines,
indicating they did not occur as a consequence of the genomic manipulations that
occurred during the process of correction. The remaining 7 unique changes were
distributed between the two lines – 3 appeared in the mutant, and 4 in the corrected
(Table 4). We do not, at this time, know whether any of the 4 unique changes found
in cWAS arose as a consequence of the process of genetic correction.
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Table 4: Array CGH analysis results for WAS and cWAS. Most variants
varian were
seen in both lines. Seven unique changes were detected. Shaded blocks indicate
positive identification, whereas white blocks mean variant was not detected in those
cells.
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We subsequently treated the targeted clone 5 with Cre-recombinase, and
assayed for the removal of the loxP-flanked Puromycin-Thymidine kinase selection
cassette. Any cells which did not undergo proper excision and retained the selection
cassette would be rendered sensitive to Thymidine kinase-induced “suicide” when
treated with Ganciclovir. After negative selection, we obtained 8 targeted corrected
WAS iPSC (cWAS) clones, containing the endogenous integration of WAS2-12 -2AGFP and one residual loxP site, as illustrated in Figure 15.
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Figure 15: Excision of selection cassette by expression of CRE-recombinase.
Schematic illustrates the expected outcome if successful excision occurred.
Removal of selection cassette was successful in 10 out of 12 cWAS clones. WAS
iPSC DNA was used as control.
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Following targeted correction and CRE-recombinase excision of selection
cassette, corrected iPSC were evaluated for pluripotency by teratoma formation
assay. As shown in Figure 16, targeted-corrected WAS iPSC (cWAS) formed a
teratoma when injected in a mouse, and gave rise to tissues from all three germ
layers, confirming maintenance of pluripotent state, and thus showing no evidence
that either ZFN activity or targeted integration at the WAS locus impaired pluripotent
function.
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e 16: Evaluation of pluripotency of cWAS iPSC by Teratoma formation
Figure
assay. Teratoma formation analysis was done at both stages of iPSC generation,
after targeted integration at the WAS locus, and also following CRE-recombinaseCRE
mediated excision of selection cassette.
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3.5 Generation of hematopoietic progenitors from human pluripotent stem
cells
Wiskott-Aldrich Syndrome is a hematological disorder that affects the function
of various cells in the immune system. Abnormal cell function results from the
absence of WASp expression. This protein functions exclusively in hematopoietic
cells, and plays a critical role in cellular function, as previously described. In order
to assess whether our correction strategy resulted in restoration of WASp
expression, we proceeded to derive hematopoietic cells from our corrected WASpatient derived iPSC (cWAS), alongside mutant WAS iPSC and WA01 or WA09
hESC.
In order to induce hematopoietic differentiation, we first adapted each of our cell
lines to a single-cell passaging method over the course of 5 weeks, as described in
Chapter 2. Once cells were adapted, we obtained single-cell preparations of each
of our lines – WAS iPSC, cWAS iPSC, WA01, and WA09 human embryonic stem
cell (HESC)- and plated 5000-7000 cells per well of a 96-well plate for generation of
spin embryoid bodies (EB). These were then cultured for 5 days in stem cell
differentiation medium under stimulation of stem cell factor (SCF), vascular
endothelial growth factor (VEGF), and bone morphogenic protein 4 (BMP4) at levels
optimized for each cell line. (Approximately 36hrs after initial culture, we observed
cell clusters acquired a three-dimensional, spherical morphology characteristic of
embryoid bodies.

At the end of 5-days in spin EB conditions, 16 EBs were

transferred to each well of a 6-well plate pre-seeded with Mitomycin C-inactivated
murine bone marrow OP9 cells and cultured for an additional 9 days (Figure 17).
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Figure 17: Spin EB in OP9-co-culture. Images capture EB changes over time in in
vitro hematopoietic differentiation culture. At day 4, post transfer to OP9 stroma,
EBs remain in suspension, but after 2-4 hours begin to attach to feeders. In the
following 10 days of co-culture, EBs begin to expand and release hematopoietic
cells onto the well.
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Within the first 24 hours, EBs attached to the feeder layer, and, utilizing timelapse live cell imaging, we could observe that, during days 3-5 in co-culture, spinEB–derived stroma spreaded out onto the well, and large fluid-filled vesicles
protruded from EBs. Within a few days, small, round cells formed inside these
vesicles, and erupted to form small distal cell clusters. By day 12-14 (total days of
culture), we observed vast cell proliferation and a significant number of cells floating
in suspension, no longer attached to the feeders (Figure 18).
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Figure 18: Time-lapse
lapse imaging of spin EB in co
co-culture. Images show
hematopoietic differentiation of spin EB in OP9 co
co-culture
culture over time. Red arrow
marks release and proliferation of hematopoie
hematopoietic
tic cells originated from EB. White
arrow marks the vesicle where most hematopoietic cells seem to grow and
proliferate prior to extravasation.
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At this time, we harvested cells from supernatant, and disrupted EBs to collect
all remaining cells still trapped inside. Once cell preparation was filtered and mostly
free of OP9 feeders, cells were counted, stained for known hematopoietic
progenitor surface markers CD34, CD43, and CD45, and analyzed by flow
cytometry. Flow Cytometric analysis revealed all three lines (WAS, cWAS, and
WA09) were capable of efficiently generating hematopoietic cells, and the
hematopoietic progenitor cells (CD34+CD43+ and CD34+CD43+CD45+) derived from
the targeted-corrected cWAS iPS line expressed GFP, as expected, providing us
with the first evidence of expression of the integrated transgenes (Figure19).
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Figure 19:: Flow cytometric detection of hematopoietic progenitor cells.
cells First
column shows CD34+CD43+ hematopoietic progenitor cells derived from both
corrected and mutant iPSC, as well as from WA09 hESC control. Second column
highlights the percentage of these cells that also express CD45. Third column
shows GFP detection in cWAS
cWAS-derived progenitors.
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We also analyzed our in vitro hematopoietic differentiation cultures for the presence
of lineage-specific progenitor cells, and identified cells expressing markers of
myeloid, erythroid, and megakaryocytic hematopoietic lineages (Figure 20).
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Figure 20: Derivation of myeloid, erythroid, and megakaryocytic cells from
WAS, cWAS, and hESC-derived progenitors.
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Moreover, when assayed for GFP expression, these myeloid, erythroid, and
megakaryocytic cells expressed GFP at a similar level to that observed for
CD34+CD43+CD45+ hematopoietic cells. Endothelial cells, which are CD43-CD45did not express GFP, as expected, and were used as negative control in this
experiment (Figure 21).
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Figure 21: GFP expression in hematopoietic cells derived from cWAS. GFP
expression derived from our integrated reporter transgene is observed in myeloid
cells, erythrocytes, and platelets, demonstrating WAS-promoter activation.
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In addition to characterization of progenitor immunophenotype, we also
performed colony-forming assays from total CD34+ cells derived from WAS, cWAS,
and WA09 in order to evaluate the in vitro differentiation potential of these cells. Our
progenitors derived from both mutant and corrected iPSC lines showed similar CFC
potential to the control WA09-derived CD34+ cells. We observed predominantly
granulocyte and macrophage colonies emerging from progenitors from all three
cells lines (Figure 22A). All colonies resulting from cWAS were GFP+,
demonstrating sustained expression of our transgene reporter (Figures 22B).
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forming assays for differentiation of hematopoietic
Figure 22: Colony-forming
progenitors. A. Average numbers of colonies obtained from each line. Two
experiments were done, each in triplicates. B. Images of colonies derived from WAS
and cWAS progenitor cells. GFP expression detected in cWAS colonies.
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3.6 Detection of WASp and GFP expression in CD34+CD43+ hematopoietic
progenitor cells derived from cWAS
The WAS gene promoter is only active in hematopoietic cells. Detection of GFP
expressing cells in cWAS iPS-derived progenitors was the first step in determining
successful targeted integration, as described above in Figure 18. To further confirm
proper transgene expression, we analyzed sorted CD34+CD43+ cells by Reverse
Transcription PCR utilizing two sets of primers- one specific for WAS and the other
anchored on both WAS and GFP (primers listed in Table 2).
As previously described, our WAS-mutant cells carry a germ line insertion of a
G at position 1305 in exon 10 of the WAS gene. In our repair donor template, the
exon 10 sequences are wild-type, thus absent of the additional G. Furthermore, as
mentioned earlier in this section, we also introduced a silent base-pair change
earlier in exon 10 of our donor, which replaced the existing XhoI site with an XbaI
restriction enzyme site. Therefore, a simple endonuclease digestion would facilitate
detection of correct mRNA from mutant mRNA.
RNA was harvested from progenitor cells derived from all three lines (WAS,
cWAS, and WA09) and subsequent to reverse-transcription, cDNA was amplified in
an RT-PCR assay (Figure 23A).
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Figure 22: Expression of corrected WAS mRNA in cWAS-derived
erived progenitor
cells. A. Detection of WAS mRNA expression through RT
RT-PCR
PCR amplification of
cDNA from both WAS and cWAS hematopoietic progenitor cells. B. Sequencing of
PCR product shows base
base-pair
pair changed introduced in donor sequence (995C→A),
(995C
which results in loss of XhoI site and gain of XbaI site in corrected cells. C.
Sequencing exon 10 (1305 position) from RT
RT-PCR
PCR material derived from WAS and
cWAS progenitors show restoration of wild
wild-type
type sequence in corrected cells, as
evidenced by the loss of additi
additional G.
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In order to assay the RT-PCR product for the changes introduced in the donor
molecule, we performed Sanger Sequencing analysis, and demonstrated that
mRNA resulting from cWAS carried the silent point mutation (C→A) at position 995
and carried the wild-type sequence at exon 10 (absent of insertion G mutation)
(Figures 23B and 23C). Taken together, these data confirmed proper splicing from
endogenous exon 1 to the integrated transgene and generation of mRNA from
transgenic WAS.
We also assessed expression of WAS and GFP transgenes in mutant and
corrected progenitors by real-time quantitative RT-PCR (qRT-PCR). Using primers
anchored on both WAS and GFP, we again observed WAS mRNA and GFP mRNA
expression in corrected cells. Furthermore, in order to detect residual endogenous
mRNA that may potentially be transcribed in the corrected cells, we included in our
qRT-PCR analysis primers binding to exon 11 of WAS and the 3’UTR. The results
showed no evidence for mRNA derived from the endogenous mutant locus in
corrected cells (Figure 24).
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Figure 24: qRT-PCR analysis of WAS and cWAS progenitors for detection of
WAS and GFP mRNA expression. Top panel shows levels of endogenous WAS
mRNA expression. No endogenous WAS mRNA is detected in cWAS-derived
progenitors. Middle panel shows expression of transgene WAS (detected using
primers in both WAS and GFP) in cWAS-derived progenitors. Bottom panel shows
the corresponding expression of integrated GFP reporter transgene.
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Driven by the encouraging results from mRNA analysis, we proceeded to assay
our cWAS progenitors for WAS protein expression. GFP expression observed in
corrected progenitor cells by flow cytometry provided the first evidence suggesting
proper function of transgene in generating protein. Determining expression of
transgenic WASp was the next step to confirm correction. Sorted CD34+CD43+
progenitor cells were fixed and permeabilized and stained for WASp. Flow
cytometric analysis results revealed WASp expression in both cWAS and WA09derived progenitors when compared to isotype (Figure 25). We observed a shift in
the mean fluorescence intensity (MFI) value for cWAS-progenitors when compared
to the isotype control. This shift was also similar to that observed for WA09-derived
normal progenitor cells. A small shift was detected in mutant progenitor cells.
Because the antibody used for WASp detection may have a low level of crossreaction to a close family member, N-WASp, we believe this small shift may have
resulted from binding to N-WASp.
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Figure 25: Detection of WASp by intracellular immunostaining and FACS
analysis. Hematopoietic
ematopoietic progenitors derived from WAS, cWAS, and WA09 hESC
were assayed for expression of WASp. Histograms were overlayed for comparison.
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For a final confirmation of WASp expression we assayed protein lysates by
Western Blotting. This analysis showed restoration of protein expression in our
gene-corrected hematopoietic cells, and also demonstrated absence of WASp in
our patient-derived WAS progenitors, as expected (Figure 26).
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Figure 26:: Western Blot analysis of hematopoietic progenitor cells for
detection of WASp.. Shift in size of WASp expressed in cWAS progenitors is due to
fusion with residual 19 amino acids from “2A tag”.
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We also observed that the WASp band detected in cWAS-derived progenitors
appeared at a higher molecular weight (approximately 63kD, instead of the
expected 60kD). This is consistent with what has been reported for constructs
linked by a 2A peptide. During translation, after ribosome skipping and subsequent
cleavage at the 2A site, approximately 19 amino acids from the peptide remain
attached to the upstream protein, which explains the shift in size [80].

3.7 Natural Killer (NK) cell differentiation from iPSC-derived CD34+CD43+
progenitor cells
Natural Killer (NK) cells are part of the innate lymphoid system, and play an
important role in immune defense against viral infection and cancer [81]. These
cells comprise 10-20% of all mononuclear cells, and, unlike T-cells, NK cells lack Tcell receptor (TCR), and kill a wide range of targets in a manner that is independent
of human leukocyte antigen (HLA)- recognition [82,83]. In WAS patients, NK cells
lack WASp expression and display impaired cytotoxic function, which contributes to
immunedeficiency in these patients [17].
In order to demonstrate restoration of immune function as a consequence of
WAS correction, we derived NK cells from CD34+CD43+ progenitors from WAS and
cWAS iPSC, and WA09 hESC in a well-established NK-specific co-culture-based
assay reported to give rise to cytotoxic, mature cells capable of killing tumor cell
targets [84,85] (Figure 27).
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Figure 27: In vitro Generation of NK cells. Panels show expression of NK-specific
NK
markers. A noticeable deficit in generation of NK cells is shown for WAS-derived
WAS
progenitor cells in the second column, where the low percentage of CD56+ cells is
highlighted.
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At the end of approximately 30 days, flow cytometric analysis showed robust
generation of a distinct CD56+ population from both WA09 and cWAS progenitors,
consistent with NK phenotype (Figure 27). Furthermore, these cells expressed NK
receptors CD16, and CD94. Our mutant progenitors, however, differentiated very
poorly in 3 separate experiments, generating a very low number of NK cells. This
result was obtained irrespective of whether OP9-DL1 or OP9-DL4 stromal feeders
were used for the differentiation process.
We confirmed WASp expression in cWAS-derived NK cells by Western
Blotting. Due to the very low number of NK cells obtained through in vitro
differentiation, there were not enough cells for Western Blot analysis. As seen with
the progenitors, we observed the WASp band appeared at a higher molecular
weight, consistent with the shift we expect for a WASp-2A fusion (Figure 28).
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cells. Lane 1 shows WASp
Figure 28:: Western Blot analysis of WASp in NK cells
expression in total PBMC; Lane 2 shows WASp expression in NK cells isolated from
peripheral blood of normal donor; Lanes 3
3-5
5 show expression of WASp in in vitro
differentiated NK cells (respectively, from cWAS iPSC
iPSC-derived
derived progenitors, umbilical
um
cord

blood-derived
derived

iPSC
iPSC-derived
derived

progenitors,

and

from

hematopoietic progenitors obtained from umbilical cord blood).
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primary

CD34+

A lower-molecular weight band was detected in NK cells derived from cWAS
progenitors. We do not yet have knowledge of what it may be. Sanger sequencing
analysis of RT-PCR product from corrected NK cells revealed transcription of only
the transgenic WAS RNA, carrying both the C→A change at base-pair position 995
in exon 10, and the corrected, wild-type sequence at position 1305 (where original
germline insertion of G occurred) (Figure 29). These data suggest the lower band
observed in Western Blot does not result from mutant protein, which is consistent
with our findings that neither WAS mRNA nor WASp is detected in the mutant
CD34+CD43+ progenitor cells, as shown in Figures 28 and 29.
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PCR analysis of WAS gene expression in corrected NK cells.
Figure 29: RT-PCR
Figure A shows silent base
base-pair change at position 995 (C→A)
A) indicated with back
arrow. Figure B shows normal, wild
wild-type
type sequence only present in RNA, absent of
insG mutation (underlined in red).
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In order to assay restoration of function in corrected NK cells, we evaluated the
ability of in vitro generated NK cells to respond to K562 erythroleukemia cells in coculture assays and detected a remarkable difference in the expression levels of
pro-inflammatory cytokines interferon gamma (IFNγ) and tumor necrosis factor
alpha (TNFα) between mutant and corrected NK cells. Mutant NK cells were
deficient in their ability to respond to K562 cells (Figure 30), while cWAS-derived NK
cells showed an upregulation in the levels of both IFNγ and TNFα cytokines,
demonstrating restored function.
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IFNγ and TNFα cytokine responses upon coFigure 30:: Upregulation of IFN
culture with K562 cells. Upregulation of cytokines associated with NK cell
cytotoxic function.
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3.8 Isolation of purified Revertant lymphocyte populations from WASrevertant patient’s peripheral blood mononuclear cells (PBMC)
We obtained whole blood samples from two WAS-revertant patients, namely
WAS4 and WASJ. Both patients are known to carry the same WAS germline
mutation: a base-pair change at position 995 of exon 10 (C995T) which results in a
premature stop codon, and the loss of the original arginine amino acid at this
position on the WAS protein. Consequently, a truncated protein is produced, which
lacks the catalytic VCA domains necessary for proper function.
In order to detect revertant cells in different lymphocyte populations, we first
performed a negative isolation utilizing antibody-bound magnetic beads to obtain
purified lymphocyte populations. Subsequent to magnetic isolation, we analyzed
cells by immunostaining and flow cytometry to isolate specific subpopulations:
CD4+, CD8+, CD4+CD45Ro+, CD8+CD45Ro+, and CD8+CD45Ro-. We identified
WASp+ and WASp- populations within each of these groups (Figure 31).
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Figure 31: Flow Cytometric analysis and detection of WASp+ lymphocytes in
PBMC samples isolated from WAS4 and WASJ revertant patients. Panel A
shows detection of WASp+ CD4+ and CD8+ T-cells
cells in patient WAS4. Panel B shows
detection of WASp+ CD4+ and CD8+ T-cells
cells in patient WASJ. Panel C shows
analysis of CD4+ and CD8+ T-cells
cells for the presence of memory (CD45R0) and naïve
(CD45RA) WASp-expressing
expressing cells.

111

Each sorted population was subsequently lysed and a 260bp-region neighboring the
germline mutation site was amplified using primers labeled with specific identifier
sequences for each cell population (Figure 32 and Table 5). Purified PCR material
was subsequently prepared for 454 sequencing analysis.
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Figure 32: Schematic illustrating PCR strategy for amplification of material
from individual cell populations of lymphocytes isolated from WAS-revertant
WAS
patients. Primers contain identifier sequences attached at the 5’ end which allow
for labeling amplicons from each population.
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Table 5:: List of multiplex identifier sequences utilized for labeling of each
lymphocyte population from WAS4 and WASJ patients.
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3.9 Detection and Characterization of revertant genotypes in WASp+
lymphocytes from WAS revertant patients
The emergence of WASp+ lymphocytes in patients carrying deleterious WAS
germ line mutations suggests that restoration of protein expression must have
occurred by mechanisms that somehow overcame the original defect. Our goal was
to investigate the molecular events (either site-specific reversion of original mutation
or second-site mutations) that occurred in the revertant cells to provide restoration
of protein expression.
With the advent of next generation sequencing (NGS) technology, obtaining
large volumes of genomic sequence data is easily attainable. Moreover, this
powerful technology allows for ultra-deep DNA analyses, able to detect even those
events that appear at very low frequencies. Using the Roche 454 GS Titanium
Amplicon NGS platform, we sequenced a 260-bp segment of the WAS gene
encompassing the germline mutation (C→T at position 995 in exon 10) in 2 WASrevertant patients, WAS4 and WASJ.
In order to generate purified material for NGS, we PCR-amplified each desired
region from sorted WASp+ cells for each patient, and, in some cases, also from
WASp- cells as a control. Each different cell population was amplified with primers
containing a unique multiplex identifier (MID) sequence (listed in table 4), and thus
libraries from each population were generated. This feature allowed us to sequence
several libraries together in a multiplex fashion, and later deconvolute the data in
the analysis software using the MIDs as a tool for sorting amplicons from different
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populations. Subsequent to amplification, samples were purified on Ampure beads
and purity was assessed on a bioanalyzer. Sample quality and purity are crucial for
efficient sequencing. Contamination with even slight amounts of residual primer
dimer, for instance, can affect sequencing results significantly. Once samples were
ready, we combined libraries for each patient, and following clonal amplification in
microbeads in an oil emulsion, each library was bi-directionally sequenced using the
Roche 454 Amplicon sequencing platform. Following comprehensive analysis of
individual cell populations, we identified hundreds of revertant genotypes in our
patient set. With ultra-deep sequencing analysis, we identified, in this study, over a
hundred potential revertant genotypes in the sorted WASp+ cells of both P1 and P2,
some of which occurred at low frequencies and could only be detected with a more
powerful approach such as NGS. In this report we will outline two classes of
reversions identified: Class I reversions (base-pair changes occurring directly in the
germline mutant codon), and Class II reversions (genotypic changes in intron 9
affecting splicing).
Following intracellular immunostaining and flow cytometric analysis, we
identified WASp-expressing cells in T-lymphocytes from both patients. Because we
had greater amount of sample from WAS4, we were able to also analyze memory
and naïve T-cells subsets for this patient.

We compared our findings for the

memory and naïve populations, and observed that an Adenine at position 995
(replacing the stop codon with an arginine) was the most frequent class I genotype
found in both CD4+ memory T-cells and CD8+ naïve T-cells. However, in the CD8+
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memory T-cell population, the predominating class I reversion was a 996G→C
(replacing the premature stop codon with a serine amino acid) (Table 6).
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Table 6: Summary of Class I revertant genotypes detected in memory and
naïve T-cells from WAS4.
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We also looked at the class II changes across memory and naïve T-cell
populations from patient WAS4, and found a large number of base-pair changes
present. As noted in table 6, a direct comparison between naïve and memory CD8+
T-cells showed highest predominance of reversion in the memory population.
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Table 7: Summary of Class II reversions identified in memory and naïve Tcells from WAS4.
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We also compared the pattern of reversions between WAS4 and WASJ. This
analysis showed both patients possessed Class I and Class II reversions.
Interestingly, for patient WAS4, in both total CD4+ and total CD8+ T-cells, the most
common Class I reversion was 995T→A ,restoring the original Arginine amino acid,
and thus encoding for wild-type WAS protein (Table 7, marked in red). However, in
WASJ, though 995T→C (restoring original arginine) appeared at highest frequency
among CD4+ T-cells, the most predominant genetic change in CD8+ T-cells was
997A→C, which replaces the stop codon with the amino acid Serine (Table 7
marked in blue). These observations may suggest that reversions originated earlier
in lymphocyte development, irrespective of whether or not they fully restore wildtype protein, undergo positive selection and accumulate over time.
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Table 8: Summary of Class I reversions identified in WAS 4 and WASJ. Redenclosed data show predominant genotypic reversion in CD8+ T-cells from both
patients. Blue-enclosed data show predominant reversion in CD4+ T-cells.
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Evaluation of Class II reversions in total lymphocyte populations from both
patients revealed a greater frequency of revert ants in the CD8+ T-cells from WAS4
as well as WASJ (Table 8). Additionally, many of the more-common Class II
reversions appeared in both patients, and in some cases, across all four lymphocyte
populations (e.g. changing the original cytosine located in intron 9, 3 base pairs
upstream of exon 10).
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Table 9: Summary of Class II reversions detected in T-cells from WAS4 and
WASJ patients.
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CHAPTER 4: DISCUSSION

4.1 Genome editing in iPSC for correction of Wiskott-Aldrich Syndrome
Primary immunedeficiencies such as Wiskott-Aldrich syndrome, typically result
in very severe phenotypes. Until very recently, the only potential cure for patients
with these disorders was an appropriately matched allogeneic hematopoietic stem
cell transplant (HSCT) early in life. Despite the advancements in transplantation, the
availability of a donor greatly impacts the success of this treatment. Gene therapy
efforts are promising, but despite the good results reported in recent clinical trials
with lentiviral vectors, the current virus-mediated methods still present a serious risk
for insertional oncogenesis, due to the large number of randomly-integrated vector
inserts per patient (approximately 10,000 -25,000) [46]. Site-specific gene correction
is an attractive strategy that offers the benefit of targeting one locus on the genome,
thereby minimizing the potential for deleterious insertional events.
We have pursued a patient-specific therapeutic approach consisting of first
generating iPSC from skin from the patient, and subsequently correcting the
disease-causing mutation in vitro by virus-free HDR-mediated targeted integration in
the endogenous mutant WAS locus utilizing Zinc-finger nuclease technology. To
date, successful nuclease-mediated gene correction studies have focused on repair
of specific mutations by targeted substitution (which requires new reagents for each
intended modification) [68, 86], or transgene integration in safe harbor loci, such as
the AAVS1 locus on chromosome 19, as shown for correction of alpha-thalassemia
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and X-linked Chronic Granulomatous Disease [60, 87]. Our work is the first to
demonstrate the targeted insertion of a WAS2-12 repair transgene in the endogenous
DNA sequence. Targeted transgene integration offers significant advantages: 1) It is
applicable to nearly all mutations in a given gene; and 2) it allows for endogenous
regulation of transgene expression.
There are also significant potential advantages to correcting WAS-causing
mutations in iPSC vs. primary HSC. First, the unlimited expansion potential of these
cells ensures abundant sample availability. Second, the clonal property of iPSC
growth facilitates assessment and detection of potential deleterious genetic
changes in individual clonal populations. Lastly, although there is, at present, no
protocol for generation of transplantable hematopoietic stem cells from human
iPSC, in principle, transplantation of corrected iPSC-derived HSCs, would provide
patients with a genetically homogenous population of corrected cells. In addition,
our own studies of WAS-revertant patients suggest that restoration of WASp
expression in T-cells alone, even at low frequencies, significantly reduces the
severity of the disease, provided these cells encompass a sufficiently broad
antigen-recognition immunological repertoire [23]. Therefore, iPSC-derived genecorrected T-cell precursors could presumably also be utilized therapeutically for
treatment of WAS patients.
Our gene correction study also highlights the importance of target site selection
when designing an endogenous integration strategy. Because WAS patients may
each have a different disease-causing mutation [5], with no single mutation being
predominant among patients, proposing a correction approach that is applicable to
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most patients is a challenging task. Our goal was to target the insertion of a full or
partial WAS cDNA construct to the mutant WAS locus, at a site near the start of the
WAS gene, and in this way cover almost all possible mutations, while allowing for
endogenous control of transgene expression.
For our initial studies in K562, we tested two sets of ZFN, both of which cleaved
a sequence early in the WAS gene, and therefore were suitable candidates for our
strategy (Figure 9). We observed S4-ZFN targeting intron 1 offered two major
advantages compared to S1-ZFN: higher targeting efficiency and low toxicity. Codelivery of ZFN and donor to K562 cells resulted in targeted integration at the WAS
locus, and even with significant increase in size of donor molecule, the integration
efficiency did not reduce dramatically. When co-delivering a 1.6kb PGK-GFP donor,
we detected sustained GFP expression over a period of 4 weeks. PCR-analysis
showed correct targeting in 30% of the WAS alleles (Figure 10). It is possible that,
because K562 are female cells (thus carrying two copies of the WAS gene), both
alleles were targeted in specific cells. We, however, did not further investigate this
possibility. We also analyzed DNA from GFP+ cells transfected with the donor
plasmid only. These cells, though stably expressing GFP, did not show integration
in intron 1 of WAS, indicating expression arose from a random integration
somewhere else in the genome. K562 are a tumor cell line [78] and, as such,
intrinsic genomic instability likely results in random DSB which can facilitate
integration of donor DNA.
Encouraged by our preliminary gene targeting data, we built our final donor
construct comprised of WAS exons 2 through 12, preceded by a splice acceptor, in
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order to allow proper splicing of our transgene. For the purpose of correction of
WAS iPSC, we added a puro-TK selection cassette to the donor construct. Since
pluripotent cells proliferate robustly in culture, the puromycin resistance facilitated
identification of targeted clones. Though our overall targeting efficiency may initially
seem low, with 7 clones (out of 2x106 nucleofected cells) resulting after puromycin
treatment (Figure 13), almost all of them (6 out of 7) had the desired insertion in
intron 1. This observation suggested high specificity of ZFN activity, and indicated
proper homology-directed repair of ZFN-induced DSB. We initially expanded clones
2 and 5 in culture and, over the course of several passages, observed close 5 was
more stable in culture, maintaining a pluripotent, undifferentiated state over many
passages. We selected this clone for Southern blot analysis. Utilizing a probe
against the puromycin gene, we confirmed the presence of only the intended
integration, at intron 1 of the WAS locus.
Zinc-Finger nuclease technology has been extensively studied, and various
studies have shown successful targeting of genomic loci using ZFNs, some of which
have already moved into clinical trials [91,88]. Though the efficacy of these reagents
has been confirmed through these various studies, off-target effects of ZFN activity
have been previously reported [59, 89-90, 92], with the extent of such effects
varying depending on the ZFN and the target sequence. In order to analyze our
cells for potential deleterious genomic effects due to ZFN activity, we performed
comparative genomic hybridization array (aCGH) analysis of DNA from both mutant
and corrected iPSC against a normal, diploid control. This analysis detected a total
of thirty-two genomic changes in both the mutant and corrected iPSC lines, most of
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which were small amplifications and deletions (Table 4). Twenty-five of these were
found in both mutant and corrected cells, suggesting no association with the genetic
manipulations we performed in the course of correction. Seven unique changes
were reported between the two lines, mostly consisting of amplifications ranging
from 54kb to 88kb. Four of them were found in the corrected iPSC, and three in the
mutant. We have not examined in any detail the significance or potential
consequences of the unique changes observed.
Since WASp is exclusively expressed in hematopoietic cells, we anticipated our
ability to detect restoration of protein expression in corrected cells would first require
that we derived hematopoietic cells from our cWAS iPSC. Various groups have
reported successful in vitro generation of hematopoietic progenitors [75, 77, 94-96].
Guided by the principles established in these protocols, we derived CD34+CD43+
progenitor cells from both iPSC lines in a spin EB/OP9 co-culture, and from wildtype WA09 hES cells. Both WAS and cWAS iPSC generated high levels of
hematopoietic progenitors in 10 separate experiments. We saw no evidence of
impaired hematopoietic differentiation potential in WAS iPSC, when compared to
both corrected iPSC and wild-type control WA09.

Expression of our GFP reporter

gene was observed in the corrected progenitors, reflecting both activation of the
endogenous WAS promoter and correct splicing and expression of our transgene.
This observation was further confirmed by performing RT-PCR analysis in total RNA
harvested from WAS and cWAS progenitor cells. We detected GFP mRNA in only
the cWAS-derived CD34+CD43+ cells. Furthermore, RT-PCR analysis revealed both
mutant and corrected progenitors generated WAS mRNA, but sequencing analysis
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of the RT-PCR product showed that cDNA generated from WAS progenitors carried
the 1305insG mutation, while cWAS progenitors exclusively showed the correct
WAS transgene exon 10 sequence. Furthermore, in the construction of our repair
donor, we introduced a silent mutation at base-pair position 995 (310 bases
upstream of 1305 insertion). This change was also present in mRNA from cWAS
progenitors, providing additional confirmation of transgene expression. Western
results validated WASp expression in corrected CD34+CD43+ cells, while no protein
was detected in mutant cells, as expected. We anticipated WASp expressed from
our transgene would have higher molecular weight. This is due to the use of 2A
peptide to link both the WAS and GFP genes in the donor template. At the time of
translation, ribosome skipping occurs near the end of the 2A sequence leaving 19
amino acids of the peptide attached to the upstream protein [80]. Thus, a shift in
size of approximately 3kD is expected for the transgenic WASp.

Indeed we

observed the corrected CD34+CD43+ cells expressed a slightly larger WASp when
compared to the wild-type WASp expressed from PBMC and from hESC-derived
hematopoietic progenitor cells. Both Western Blot and FACS analysis of intracellular
WASp showed corrected cells expressed a slightly lower level of WASp than that
seen for hESC- derived progenitor cells. A possible explanation is that the presence
of an additional 19 amino acids from the “2A tag” at the C-terminus may induce
some level of premature degradation of protein.

In addition, if the ribosome

skipping at the 2A site is not 100% efficient, some of the translated WASp may be
present as a WASp-2A-GFP fusion protein, and may, consequently, be degraded.
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Our intracellular staining and FACS analysis results detected a small level of
WASp in mutant progenitor cells. Western Blot analysis, on the contrary, does not
show any detectable WAS protein in mutant progenitor cells or NK cells. At the RNA
level, however, we do detect WAS RNA in both mutant and corrected progenitors
(and the same is true for NK cells). Because the 1305insG mutation induces a
frame-shift late in the gene, it is conceivable that an aberrant protein is formed,
which is later degraded. However, Western Blot analysis shows no detectable
WASp in either mutant progenitors or mutant NK cells. What is likely occurring is
that the anti-WASp antibody used for intracellular staining exhibits a small level of
non-specific binding, perhaps to N-WASp (close WASp family member that shares
homology to WAS).
Having established the restoration of WASp expression in corrected cells, the
next step was to evaluate whether WAS gene repair correlated with reinstatement
of normal WASp-related function. Not much is known about the involvement of
WASp in normal function of HSPCs. Some studies looking at CD34+ HSPCs from
obligate female carriers revealed non-random X-inactivation occurs in the
progenitors found in the bone marrow, indicating a selective pressure against cells
carrying the mutant copy [97,98]. Furthermore, Lacout et.al. observed that WASpdeficient mice display the same impairments in cell trafficking and chemotaxis
reported in human WASp- cells. They attributed the non-random X-inactivation
pattern reported in HSPC to a defect in migration ability which significantly affects
the homing of these cells to the bone marrow [18]. WASp deficiency has also been
linked to abnormal hematopoietic proliferation and differentiation in colony-forming
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assays when primary bone marrow CD34+ cells from WAS patients were compared
to those from healthy controls [99].
We demonstrated proper progenitor function by in vitro differentiation of total
CD34+ hematopoietic progenitor cells in colony-forming assays. Day 14 spin EBderived CD34+ progenitor cells from both WAS and cWAS gave rise to macrophage
(CFU-M), granulocyte (CFU-G) and granulocyte-macrophage (CFU-GM) colonies,
however no erythrocyte lineages were observed in two separate experiments.
Though our total numbers of colonies may appear low, they are consistent with
values reported in similar work performed with in vitro hESC-derived progenitor cells
[100]. cWAS-CD34+ progenitors produced a higher number of colonies in two
different experiments (each done in triplicate), perhaps suggesting a growth and
differentiation

advantage,

though

our

numbers

never

reached

statistical

significance. All colonies derived from cWAS progenitors were GFP+, demonstrating
sustained transgene expression in progeny cells.

We speculate the apparent

lineage-restricted CFC potential (due to absence of erythromegakaryocytic
colonies) observed in our iPSC- derived progenitors is an indicator of their stage in
development. Our data show that most of the CD34+ cells present in our day14
cultures (time of harvest) are also CD43+, with a large number of those coexpressing CD45. Vodyanik and colleagues performed a detailed analysis of the
CFC potential of different subsets of CD43+ hematopoietic progenitors generated in
WA09/OP9 co-cultures, and showed that CD34+CD43+CD45+ cells expressed
surface markers indicative of a more advanced, lineage-restricted specification.
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Furthermore, they reported an association of these cells with a surge of CFC-GM/M
colonies, which supports our CFC findings [96].
We subsequently took both WAS and cWAS-derived CD34+CD43+ progenitors
through an NK-specific differentiation protocol, as previously described [101,102].
Within the first 10 days of culture, progenitor cells underwent substantial
proliferation, with an average increase of approximately 20-fold observed for both
mutant and corrected cells. Immunostaining analysis of day 16 cultures showed
cWAS progenitors gave rise to a clearly identifiable population of CD56+ NK cells,
very similar to our control WA01/WA09 cells. Phenotypic analysis of corrected NK
cells showed expression of NK-specific markers at levels comparable to those of
normal control cells. Expression of CD16 (an NK-specific lysis receptor associated
with NK cell cytotoxicity) was restored in cWAS-NK cells, whereas in mutant NK
cells it was noticeably decreased, suggesting terminal maturation of these cells is
impaired [104] Moreover, NK cells derived from cWAS progenitors expressed GFP,
providing the first indication of stable expression of the integrated transgene.
Western Blot analysis of NK cell lysates confirmed WASp was expressed in the
corrected population, at a level similar to the wild-type WA09 control. Once again,
the WASp from cWAS-derived NK cells was of slightly greater molecular weight
than wild-type WASp, consistent with residual 2A peptide. The Western Blot did not
include lysate from mutant NK cells, as the number of cells generated in the
differentiation assay was not sufficient for this analysis. Because we did not
investigate this observation further, we can only speculate that, perhaps the NK-
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specific in vitro differentiation conditions required WASp expression at a certain
point during development.
The extent of NK-cell functional abnormalities due to absence of WASp seems
to vary between patients [17]. It is known, however, that the actin cytoskeleton plays
a crucial role in activation of NK cells and T-cells [17]. The binding of NK cells to
their targets, the lysis of these targets, and the subsequent recycling of NK cells are
all events which require an intact cytoskeleton [94]. In addition, cytoskeletal
reorganization is believed to be associated with cytokinetic movements required for
polarization of the secretory machinery in the synaptic interface between the
effector cells and their target [103]. As previously described, WASp is a known key
regulator of actin cytoskeleton reorganization through its interaction with the Arp2/3
complex. Furthermore, Orange and colleagues [17] closely evaluated NK cells
derived from two WAS patients, and demonstrated WASp is required for normal
localization of F-actin to the activating immunologic synapse and the subsequent
activation of NK-cell cytotoxic function.
Based on these reports that WASp plays a significant role in activation of NK
cells, we investigated whether restoration of WASp expression in corrected cells
correlated with restoration of function. When assayed for their functionality, WAS
NK cells exhibited significant deficits in comparison to wild-type (WA01) hESCderived NK cells. Upon stimulation with K562 cells, both WA01-derived NK cells and
cWAS-derived NK cells upregulated production of interferon-γ (IFNγ) and tumor
necrosis factor-α (TNFα). These pro-inflammatory cytokines are produced by NK
cells upon activation by antigen, and are believed to be critical for NK-mediated
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antiviral defense [105-107]. Moreover, the upregulation of interferon-γ is associated
with normal NK activation and the subsequent induction of target-cell cytolysis [108,
109].

This response to stimulation was not exhibited by WAS-derived mutant NK

cells, which is consistent with previous reports that NK cells from WAS patients
show a significant reduction in their ability to bind K562 targets due to the
insufficient accumulation of F-actin at the immunologic synapse [105]. The poor
binding ability prevents proper stimulation of NK cells. Taken together, these data
indicate correction of WAS restored NK cell functionality and cytokine production
when exposed to K562 erythroleukemia cells.
During our NK differentiation work, we observed WAS-derived mutant
progenitors displayed a remarkable deficiency in generating NK cells, whereas
corrected progenitors produced NK cells robustly. This deficit in our mutant line
remained until the end of the 30-day culture, suggesting a true defect, and not
simply a delayed response to cytokine and feeder stimulation. Moreover, these
results were seen in 6 of 6 experiments, utilizing either OP9-DL1 or OP9-DL4
stromal support.
This observation suggests correction of WAS may have conferred a selective
advantage to these cells in vitro. To date, however, no data have yet reported a link
between WASp deficiency and impaired NK cell development. In fact, a closer
analysis of PBMC obtained from WAS-patients showed a significantly higher
percentage of NK cells than seen in normal individuals [17], indicating no deficiency
in NK cell generation. Interestingly, Zhang and colleagues [110] developed a
mouse model engineered to express a 1305insG mutation in exon 10 of the WAS
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gene. This mutation, like the one we have in our WAS-NK cells (1305insG), leads to
the loss of the catalytic VCA domain necessary for normal function of WASp. They
observed that, whereas humans and mice lacking WASp have modest T-cell
deficits, the mice expressing the 1305insG mutant protein showed significant
impairment in T-cell lymphopoiesis, with thymic cellularity at 12-16% of the normal
levels of thymocytes seen in wild-type mice [111]. Upon analysis of thymocyte
subpopulations, they traced this defect to a severe block occurring after TCRβ
rearrangement during T-cell development.
Based on such pronounced phenotype, Zhang and colleages hypothesize that
the 1305delG mutant WASp might have a dominant-negative effect by interfering
with the compensatory function of a redundant protein such as N-WASp (a WASp
family member, expressed ubiquitously). They believe that, in the absence of
functional WASp, N-WASp is recruited via the N-terminal domains (which are
conserved between the two proteins) to sites of activation and performs a redundant
function, compensating for the lack of WASp. Because the 1305delG mutant protein
still has an intact N-terminus, it interferes with the recruitment of N-WASp.
Additional evidence reported in other studies of WASp-deficient mice substantiates
the claim that N-WASp plays a role in murine lymphocyte development [112,113].
Similar studies have not been conducted in humans, and there is, at present, no
clear evidence of the involvement of N-WASp in human lymphocyte development.
Remold-O’Donnel’s group, through their study of two WAS-revertant patients
carrying the same 1305delG mutation, proposed that human thymocytes expressing
the mutant WASp encounter a block to differentiation at a similar time point to that
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seen in mice, after TCRβ rearrangement, and that this block creates a selective
advantage for cells which have restored WASp expression. Based on this notion,
we speculate that perhaps NK cell development is also impaired at some stage
during development in the case of our mutant cells, and that, by correcting the WAS
defect, a functional protein is produced and restores the full NK differentiation
potential.
We believe our work is innovative in many aspects. First, to our knowledge, this
is the first report of modeling WAS disease in WAS iPSC. Moreover, our targeted
endogenous integration approach for correction of a mutant gene in iPSC differs
from the many reports published thus far, which comprise of safe-harbor integration
or site-specific base-pair substitution strategies [71-73]. Lastly, by using an
endogenous knock-in GFP reporter in our donor template, we generated a useful
tool for tracking WASp expression during hematopoietic development.

4.2 Somatic Revertant Mosaicism in WAS patients

Somatic Revertant Mosaicism has been described in various hematological, as
well as non-hematological disorders [114] Wiskott-Aldrich Syndrome is among the
primary immunedeficiencies for which many revertant patients have been reported.
A world-wide research study looking at 272 patients with WAS identified a total of
30 revertant patients, thus setting the frequency of WAS somatic revertants at 11%
[115]. Occurring at this reasonably high frequency, this phenomenon has attracted
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the interest of several investigators seeking to elucidate the extent of these
reversions and how they influence disease phenotype.

Thus far, T-cells have been the most frequent subset of lymphocytes found to
carry reversions [114]. Our group was one of the first to report the discovery of
several revertant genotypes in a WAS patient [116]. The development of reversions
in WAS patients has also been observed in B-cell and NK-cells, albeit to a lesser
extent [117-119]. To date, these discoveries have resulted from Sanger sequencing
assessment of the mutation region, which offers limited depth of analysis. Most
studies have reported finding only one revertant genotype per patient. However,
the few reports identifying multiple different reversions in a given patient has raised
questions as to how diverse the revertant repertoire truly is, and whether there are
reversions occurring at frequencies that are below the threshold detected by the
current methods.

In order to address these questions, we analyzed lymphocyte populations from
3 WAS patients (previously described as revertant) using next-generation
sequencing (NGS). This methodology provides the depth of coverage that allows
detection of even low-frequency revertant genotypes. We hypothesized that our
analysis would result in identification of many revertant genotypes in a given patient.

We previously reported our finding of over 30 different revertant genotypes
in WAS4 revertant T-cells [116,119]. Those results were obtained from studies of
clonal T-cell populations. In this new study, we analyzed sorted WASp+ WAS4 Tcells, but this time using next generation sequencing analysis. With this
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methodology, we identified a much larger number of genotypic changes, some
occurring at very low frequency, which explained why they were not detected in the
first analysis. These changes constituted a mixture of point mutations, splicing
variants, as well as deletions and insertion, confirming the different classes of
genotypes we observed in our first analysis [119]. In this report, we focus on two
classes of reversions: Class I (genetic changes occurring directly in the mutant
codon), and Class II (base-pair changes found in intron 9, upstream of mutant
codon). The class I revertants likely restore a full-length WAS protein by replacing
the mutant stop codon with various amino acids. Class II reversions, on the other
hand, possibly restore expression by generating an internally-deleted or frameshifted WASp through alternative splicing, skipping the mutant codon [26].
For patient WAS4, we were able to assay not only bulk T- and B-cells, but also
memory and naïve T-cell subsets. When comparing these two populations, our
analysis showed a greater diversity of revertant genotypes in the memory cells. We
speculate this is indicative of cells that, because of restoration of WASp expression,
were able to properly respond to antigen stimulation, and remained as part of the
memory T-cell pool. It is well established that WASp plays a significant role in T-cell
activation. Though WAS patients are capable of generating T-cells, these are
unable to reach optimal levels of activation through the T-cell receptor (TCR), and
do not respond well to IL-2 stimulation [15,16]. Restoration of WASp expression
normalizes these responses, and therefore reestablishes T-cells function.
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Analogous to WAS4, our observations were that patient WASJ, though not
related to WAS4, also possessed a diverse revertant repertoire, sharing some of the
same class I and class II reversions detected in WAS4. Interestingly, in a side-byside comparison of T-cell populations from both patients, we observed that even
though both patients showed a similar variety of class I genotypes, WAS 4 had an
more diverse repertoire of class II reversions in both his CD4+ and CD8+ T-cells. We
believe this can be explained by the difference in age between WAS 4 (45 years
old) and WASJ (18 years old). Somatic reversions result from spontaneous
mutations and thus, with time, newer revertant genotypes may arise, and their
respective frequencies may increase, as it has been described previously [24].
At this time, we can only speculate regarding the mechanisms underlying the
origination of such a diverse revertant repertoire in these patients. Possible
suggested mechanisms may include DNA polymerase errors, DNA repair defect, or
exposure to genotoxic agents. We currently do not have knowledge of potential
contributions from any of these to the origination of reversions in these patients.
However, analysis of mutation rate in the PIG-A gene in WAS4 revertant Blymphocytes, showed no difference when compared to that observed in nonrevertant WAS patients and normal individuals [23].

To our knowledge, this is the first study to report ultra-deep sequencing
analysis of WAS-revertant patients. It provides an unprecedented view of
spontaneous mutation in a human organism, made possible through the selective
pressure for cells that have restored full or partial gene function.
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